The Nomination Committee of Investor AB amends its proposal with an additional proposed Member to the Board of Directors

The Nomination Committee of Investor AB presented its proposals to the Annual General Meeting on April 1, 2015. The Annual General Meeting will be held on May 12, 2015. Proposals and motivated opinion can be found on the Company’s website, www.investorab.com. The Nomination Committee has decided to amend its proposal by proposing an additional person, Sara Öhrvall, to be elected as new Member of the Board of Directors. Sara Öhrvall is a Swedish citizen and was born in 1971. Sara Öhrvall is co-founder and Senior Advisor of MindMill Network, Member of the Board of Directors of Bonnier News (including the Board of Expressen, DN and DI), Bonnier Books, Bisnode, Kicks, Bonnier Publications, Nobel Museum and Umeå University. Sara Öhrvall has a broad experience of inter alia digital products, markets and media, and of product development and branding strategy. Sara Öhrvall was a Member of the Management Group at Bonnier AB 2008-2013, responsible for R&D. Sara Öhrvall was based in San Francisco 2009-2011. Sara Öhrvall’s previous experiences also include founder and Chief Executive Officer at Ninety Concept Development 2003-2008, partner and Chief Executive Officer at Differ 1998-2003, Niche Concepts Manager and Market Area Manager for Hong Kong, Taiwan and China at Volvo Cars Corporation 1995-1998, and Project Manager (marketing strategy analysis) at Toyota Motor Corporation 1994-1995. Sara Öhrvall is considered as independent in relation to Investor and Investor’s executive management as well as to Investor’s major shareholders. The Nomination Committee is of the opinion that Sara Öhrvall will add additional valuable expertise and experience to the Board of Directors and is very well suited as Member of the Board of Directors of Investor. In order to assess the demands imposed on the Board as a consequence of the Company’s current position and future direction, the Nomination Committee has discussed the size and composition of the Board, e.g. in terms of competence, industry and international experience, and diversity. With the additional proposal, four women and six men are proposed as non-executive Members of the Board of Directors. The percentage of women thereby increases to 40 percent from 25 percent compared to the Board of Directors elected at the Annual General Meeting 2014. In respect of nationality 27 percent of the proposed Board of Directors are non-Swedish citizens and 18 percent are non-Scandinavian citizens.   Information about all persons proposed as Members of the Board of Directors of Investor can be found on Investor’s website, www.investorab.com, and will, free of charge, be sent to the shareholders who request the Company to do so. The members of the Nomination Committee of Investor are Hans Wibom (Wallenberg foundations, Chairman of the Nomination Committee), Peder Hasslev (AMF), Lars Isacsson (SEB Foundation), Ramsay Brufer (Alecta) and Jacob Wallenberg (Chairman of the Board). The Nomination Committee's amended proposal results in the following adjustments in relation to the Nomination Committee’s already submitted proposals. The number of Members of the Board of DirectorsThe Nomination Committee proposes eleven Members of the Board of Directors and no Deputy Members of the Board of Directors. Members of the Board of DirectorsThe Nomination Committee proposes Sara Öhrvall to also be elected as new Member of the Board of Directors. The compensation to the Board of DirectorsThe proposal of an additional Member of the Board of Directors entails, as the only change in the Nomination Committee's proposal regarding compensation to the Board of Directors, adjustment of the proposed total value of the compensation and the maximum amount that can consist of synthetic shares. Thus, the proposed total compensation to the Board of Directors is SEK 9,021,000 in accordance with the following: (i) SEK 7,965,000, whereof SEK 2,340,000 to the Chairman and SEK 625,000 to each of the other nine Members of the Board which are not employed by the Company in cash and in so-called synthetic shares and, (ii) SEK 1,056,000 in cash as remuneration for work in the committees of the Board of Directors. Of the proposed total value of the compensation to the Board of Directors, (SEK 9,021,000), not less than SEK 0 and not more than SEK 3,982,500 shall consist of synthetic shares. The Nomination Committee of Investor AB (publ)

Nickel Mountain Group completes first set of environmental tests on waste rock samples from the Rönnbäcken Nickel Project.

As a part of the extensive test work included in the Pre-Feasibility Study (PFS), Nickel Mountain Group (NMG or the company) is undertaking detailed analysis on a series of waste rock samples in order to determine the possible environmental effect of these rocks being exposed to weather and wind. NMG has received the results from the first four waste rock samples from the Rönnbäcken Nickel Project to undergo environmental testing; these samples have been selected from representative rock types present in the drill cores from Rönnbäcken. This first batch of samples serve dual purposes, the first purpose is to establish whether the routines and methods selected for the test work are suitable and the second purpose is to establish a first base line with regard to the environmental behaviour of the rocks. The tests, both static and kinetic tests, have been supervised, coordinated and reported by Golder Associates in Luleå, Sweden. The samples were first subjected to whole rock analysis by ALS Minerals using method Me-Ms61m to establish reliable values for the waste rock composition prior to the actual environmental tests. Following this the samples were subjected to Acid Base Accounting (ABA) tests including the determination of Net Neutralisation Potential, Maximum Potential Acidity, Neutralization Potential (NP) and Fizz rate, Neutralisation Potential Ratio (NP:MPA), Paste pH, Total Sulphur, HCl-leachable Sulphate, Sulphide content, Total Sulphate (Carbonate leach) and the Inorganic Carbon (CO2) content. The third test procedure was Shake Flask tests following the European EN 12457-3 standard to determine the immediate leachability of elements from the samples. The fourth and final test was Humidity Cell kinetic testing for a period of 40 weeks following the standard ASTM D5744-96 (2001) method. The results of the tests are very promising, all four rock samples display low or very low discharge rates for all elements and stable long term trends have been established illustrating that the humidity cell test cycles have continued well beyond the time necessary to establish reliable results. Worth noting is that some critical elements such as Chromium, Zinc and Nickel have extremely low discharge rates, so low in fact that the values usually are below the detection limit of the analysis procedure. From the Acid Base Accounting and Shake Flask Test the company would like to highlight the following results: · All four tested samples exhibit a Neutralization Potential Ratio above 10 with no risk producing ARD (acid rock drainage) · All four samples exhibit a sulphide sulphur content equal to or less than 0.1 weight-% · Shake flask test results compared to European drinking water standard show low concentrations · Leaching rates in the shake flask test are very low for most elements compared to leachate limits used for waste classification (NFS2004:10) and all criteria for Inert classification are fulfilled. Mr Torbjörn Ranta, CEO of Nickel Mountain group commented that “This is a significant milestone for the Rönnbäcken Nickel Project regarding the environmental presumptions, encouraging us to continue with further technical, environmental and economical investigations needed for a pre-feasibility study”. For and on behalf of the Board of Directors of Nickel Mountain Group AB Torbjörn Ranta Managing Director For information, please contact Torbjörn Ranta Mail: torbjorn.ranta@nickelmountain.se Tel: + 46 8 402 28 00 Cell Phone: +46 708 855504 Cautionary Statement: Statements and assumptions made in this document with respect to Nickel Mountain Group AB’s (“NMG”) current plans, estimates, strategies and beliefs, and other statements that are not historical facts, are forward-looking statements about the future performance of NMG. Forward-looking statements include, but are not limited to, those using words such as "may", "might", "seeks", "expects", "anticipates", "estimates", "believes", "projects", "plans", strategy", "forecast" and similar expressions. These statements reflect management's expectations and assumptions in light of currently available information. They are subject to a number of risks and uncertainties, including, but not limited to, (i) changes in the economic, regulatory and political environments in the countries where NMG operates; (ii) changes relating to the geological information available in respect of the various projects undertaken; (iii) NMG’s continued ability to secure enough financing to carry on its operations as a going concern; (iv) the success of its potential joint ventures and alliances, if any; (v) metal prices, particularly as regards nickel. In the light of the many risks and uncertainties surrounding any mineral project at an early stage of its development, the actual results could differ materially from those presented and forecast in this document. NMG assumes no unconditional obligation to immediately update any such statements and/or forecasts.

Breakthrough for secure mobile services in Swedish healthcare

The solution with Tactivo provides swift and secure access to the prescription tool Pascal from iPhone or iPad using SITHS-card login, an identification card for Swedish care professionals. Pascal has over 50 000 users within the municipalities and private careproviders for prescription of medicals distributed in dosage bags.”The approval of Tactivo for mobile access to Pascal is a breakthrough for secure mobile services within Swedish healthcare and we are certain that more care systems will follow this development. There are many situations where mobile access to patient information can improve quality for both staff and patients, and at the same time protect confidentiality through two-factor authentication”, says Håkan Persson, CEO Precise Biometrics.The mobile solution with Tactivo makes it possible for care providers to reduce staff workload and implemement a more efficient way of working that provides staff with access to accurate and secure information, independent of location."We have been waiting a long time to use Pascal on mobile devices in a secure fashion. Thanks to Tactivo it is now possible for our staff to be more effective in their work with the patients. We can increase our presence with the patients not having to return to the office to update patient files on medication. This solution also increases patient security as we always have access to accurate information”, says Lise-Lotte Carlsson, system administrator, Kungsbacka municipality.Beside iPhone, iPad and Tactivo, the solution consists of the access service Mobilt SITHS from Svensk e-identitet and the log-on application NetID from SecMaker. As part of the approval process, Nordic Medtest has evaluated that the solution follows security requirements for usage of patient data on mobile devices.Pascal is owned and administered by Inera, the Swedish county and regional e-health company. The system is scheduled to be deployed on April 24, when it will become accessible for all Pascal users. For more information about Pascal mobile access, please visit; http://precisebiometrics.com/smart-card-reader/healthcare-solutions/About TactivoTactivo is a product portfolio of form-fitted smart card readers that provides convenient and secure access to restricted resources from mobile devices. Tactivo reduces workload for caregivers, increasing productivity, ensuring a more efficient way of working and allow staff to spend more time with patients. Tactivo is also available for Android.This press release contains information that Precise Biometrics is required to disclose pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication at 08.00 am on April 21st, 2015.iPhone and iPad are trademarks of Apple Inc., registered in the U.S. and other countries. iPad Air and iPad mini are trademarks of Apple Inc.

Transcom: Interim report 1 January – 31 March 2015

” Transcom’s like-for-like revenue increased in the quarter, and we also saw our EBIT margin strengthen. Net income significantly improved compared to last year.” Johan Eriksson, President & CEO of Transcom Key highlights · Like-for-like revenue increase by 2.4%, mainly driven by higher volumes in the North Europe and Iberia & Latam regions · Profitability improvements in the North America & Asia Pacific and Iberia & Latam regions · EBIT margin improved from 3.4% to 3.7%. Excluding since-divested CMS business and a positive one-off effect in the collections business in Q1 2014, the margin improvement was 2.1 percentage points. · Significant improvement in net income to €5.3 million (€1.6 million in Q1 2014) Q1 2015 financial highlights · Revenue €160.9 million (€160.1 million in Q1 2014). Adjusted for exchange rate impact and divested operations, revenue increased by 2.4% · Gross margin 19.6%, a 1.1 percentage point decrease compared to Q1 2014 (20.7%) · EBIT €5.9 million (3.7%) compared to €5.4 million (3.4%) in Q1 2014. · EPS 20.5 Euro cents compared to 6.2 Euro cents* in Q1 2014.* EPS for 2014 has been adjusted to reflect the reverse split as if it had occurred per January 2014 Comments from the President and CEO Both like-for-like revenue and EBIT margin improved in the first quarter. We saw higher business volumes in the North Europe and Iberia & Latam regions, while the profitability improvement was mainly driven by better performance in the North America & Asia Pacific and Iberia & Latam regions. We report a significant improvement in net income compared to last year.LIKE-FOR-LIKE 2.4% REVENUE INCREASE On a like-for-like basis, adjusting for divestments and currency effects, revenue increased by €3.8 million (+2.4%).  This growth was mainly generated by increased business volumes in North Europe and Iberia & Latam. EBIT MARGIN IMPROVEMENT Transcom’s EBIT margin in the quarter was 3.7% compared to 3.4% in Q1 2014 (1.6% excluding since-divested CMS business and a one-off effect in the collections business). Performance improvements in the North America & Asia Pacific and Iberia & Latam regions contributed positively. Profitability in the North region was flat, while we saw a decrease in the EBIT margin in the Central & South Europe region, mainly as a result of lower volumes in Italy and the start-up of new client projects in the region during the quarter. Net income improved significantly, to €5.3 million in Q1 2015 from €1.6 million in Q1 2014, as a result of decreased income tax and an improvement in net financial items. FOCUS ON OUR STRATEGIC PRIORITIES Transcom’s strategic priorities are informed by our vision of being recognized as a global leader in customer experience. We aim to grow together with our clients, further strengthening Transcom’s position as a strategic partner, while also seeking to strengthen Transcom’s global footprint. Transcom is currently starting up new projects with a number of clients, not least with existing clients with whom we are growing in new geographies. In this context, I am very pleased that Frost & Sullivan recently recognized Transcom’s growth in Peru and the Philippines by awarding us the Peru Frost & Sullivan Award for Growth Excellence Leadership, as well as the Frost & Sullivan Philippines Contact Center Outsourcing Growth Excellence Leadership Award. We are also striving to continuously improve our service offering, focusing on advanced, value-added services. I am delighted that Frost & Sullivan has recognized Transcom in the innovation area as well. On April 13, it was announced that Transcom has won the 2015 European Frost & Sullivan Award for Visionary Innovation Leadership. This award is presented every year to a company that has demonstrated the understanding to leverage global Mega Trends and integrate the vision into processes to achieve strategic excellence. Finally, it is important that we ensure that Transcom has a competitive operational platform, i.e. that our global business operations are efficient and effective. In 2015, we will focus on driving margins through maximizing our process and technology scalability, not least by increasing the degree of process and system standardization across our global operations. Pär Christiansen, our current CFO, will have a key role in this context, as he transitions into his new role as COO in June. Our new CFO, Ulrik Englund, will start his position at Transcom on June 15. Johan Eriksson, President and CEO of Transcom The interim report is also available for download on www.transcom.com Results Conference Call and Webcast Transcom will host a conference call at 10:30am CET (09:30am UK time) on Tuesday, April 21, 2014. The conference call will be held in English and will also be available as webcast on Transcom’s website, www.transcom.com. Dial-in information To ensure that you are connected to the conference call, please dial in a few minutes before the start in order to register your attendance. No pass code is required. Sweden: +46 8 505 564 74 UK: +44 203 364 5374 US: +1 855 753 2230 For a replay of the results conference call, please visit www.transcom.com to view the recorded webcast of the event. -------------------- Transcom WorldWide AB (publ) discloses the information provided herein pursuant to the Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 21, 2015 at 08:00 AM CET. For further information please contact: Johan Eriksson, President and CEO                                     +46 70 776 80 22 Pär Christiansen, CFO                                                          +46 70 776 80 16        Stefan Pettersson, Head of Group Communications            +46 70 776 80 88

Interim report for 1 January – 31 March 2015

First Quarter · Net sales, excluding divested operations, increased by 8%, amounting to SEK 1,196.5 (1,105.0) million. Including divested operations, net sales rose by 6%, amounting to SEK 1,196.5 (1,133.2) million · Operating profit excluding divested operations and non-recurring items amounted to SEK -16.4 (-0.5) million. Including divested operations and non-recurring items, the operating profit amounted to SEK -34.3 (0.1) million · Operating profit excluding divested operations, non-recurring items and Qliro Financial Services amounted to SEK -1.3 (-0.5) million · Net income amounted to SEK -29.4 (-4.2) million · Earnings per share amounted to SEK -0.20 (-0.03) · Cash flow from operations amounted to SEK -219.9 (-167.7) million CEO statementPaul Fischbein, President and CEO comments: "Qliro Group´s sales momentum continues and all segments report solid growth in the first quarter. Even with significant investments in the business, the underlying operating result is in line with the first quarter 2014. Nelly grew more than 15% and the trend in our domestic market, Sweden, remained solid with growth surpassing 20%. The share of private label sales climbed during the quarter and reached 37%. Lekmer continues to demonstrate excellent growth and reports a 45% increase in sales. Tretti reported 15% growth and gross merchandise value from merchants at CDON Marketplace increased by 83%. At the same time, the number of affiliated external merchants now exceeds 500. Gymgrossisten reported growth of 7%. Nelly’s operating income improved despite the negative impact of a stronger USD. Gymgrossisten is also affected by a stronger USD, but nonetheless reported an EBIT margin of almost 8%. The development in Qliro Financial Services during the quarter was according to plan and we applied for a license to become a credit market company. Roll-out of the payment solution was progressing in Sweden with the affiliation of Gymgrossisten. The payment solution has also been introduced to external merchants. Qliro was also launched in Finland at the start of the second quarter and we look forward to the continued expansion of the payment solution, which is advancing through both external customers and new countries. We continue to invest in our operations. Besides ongoing investments in the payment solution, Lekmer relocated its warehouse operations to Stockholm at the end of the quarter. CDON’s warehouse consolidation went ahead as planned and is expected to be completed during the third quarter of 2015.” ***For additional information, please visit www.qlirogroup.com or contact: Paul Fischbein, President and Chief Executive OfficerPhone: +46 10 703 20 00 Investor and analyst enquiries:Nicolas Adlercreutz, CFOPhone: +46 70 587 44 88E-mail: ir@qlirogroup.com Press enquiries:Fredrik Bengtsson, Head of CommunicationsPhone: +46 70 080 75 04E-mail: press@qlirogroup.com About Qliro GroupQliro Group is a leading e-commerce group in the Nordic region. Established in 1999, the Group has expanded its product portfolio and is now a leading e-commerce player within consumer goods and lifestyle products through CDON.com, Lekmer, Nelly (Nelly.com, NLYman.com, Members.com), Gymgrossisten (Gymgrossisten.com/Gymsector.com, Bodystore.com, Milebreaker.com) and Tretti. The payment service solution Qliro is also part of the Group. In 2014, the Group generated earnings of SEK 5.0 billion.Qliro Group’s share is listed on the NASDAQ Stockholm MidCap list under the ticker symbol “QLRO”. The information in this interim report is that which Qliro Group AB is required to disclose under the Securities Markets Act. This information was released for publication at 08.00 CET on 21 April 2015.

Interim report January – March 2015

·Net sales increased by 72% to 111.4 (64.9) MSEK ·Operating income amounted to 2.1 (2.3) MSEK ·Net income amounted to 3.8 (3.6) MSEK ·Earnings per share amounted to 0.21 (0.20) SEK ·9 (7) EBM systems were delivered during the period ·Order intake increased to 10 (6) EBM systems  Telephone conference with CEO Magnus René and CFO Johan Brandt April 21, 2015 at 2.00 p.m. (CET)The conference will be conducted in English. Phone numbersSE: +46 8 566 426 61UK: +44 203 428 14 10US/Canada: +1 855 753 22 36 Link to presentation: Arcam Q1 report (https://event.onlineseminarsolutions.com/eventRegistration/EventLobbyServlet?target=registration.jsp&eventid=973636&sessionid=1&key=DFC0122ECF84ED91223857A1AB2DB061&sourcepage=register) Continued strong growth Arcam continues to develop rapidly and during the first quarter the growth was over 70%, of which 30% was organic growth. Sales for the first quarter grow to 111.4 MSEK and trailing twelve months sales amounts to 385.4 MSEK. Operating profit for the period amounts to 2.1 MSEK and trailing twelve months the operating profit was 19.5 MSEK.The weak operating profit in relation to the strong growth is due to increased production capacity that is not yet fully utilized. The order intake during the period was 10 EBM systems and the order book by the end of the period was 20 EBM systems. While sales of our EBM systems continues to grow, also our acquisitions the metal powder manufacturer AP&C in Canada, and contract manufacturer DiSanto in the US grow. We now have an offering to our clients with our EBM systems as a hub and metal powders and contract manufacturing being important supplementary products broadening our offering to the market and providing recurring sales. Business status We received 10 new orders in the period and we see a continued strong demand, particularly from the aerospace industry. The order from GKN, which was presented in March, is an important key reference and a break through. Together with GKN we will take the next steps towards fully industrializing our EBM technology in the aerospace industry. Sales of metal powders at AP&C continues to grow. At the end of 2014 a third powder reactor was installed and the increased capacity is a prerequisite for continued growth.During the quarter, we also invested in production equipment at AP&C in order to streamline production to meet the demand for higher volumes. The demand for contract manufacturing was weaker around the turn of the year but production is now increasing again. During the quarter, we have received several significant new customers to the EBM part of contract manufacturing. The growing interest and increasing knowledge of Additive Manufacturing and 3D printing gives us new customers in new industry segments. This may long term lead to a broadening of our product applications. Of the 9 systems that we shipped during the quarter the main part went to customers in the implant or the aerospace industry. A strengthened organization During the quarter, we strengthened our sales and support organization in the US through the recruitment of a President for the EBM business in the US. Thus, we consolidate the administration and logistics for the North American part of the EBM business to a new base in Boston.In the UK we have inaugurated a new office in Warwick and we have strengthened our team with new employees in sales and support.With the new local offices, we move management, customer relations and logistics closer to our customers. We can then better meet customer needs for local service. During the quarter, we started a major expansion of our production facilities located in Mölndal. The expansion, which means that we will double our production area, will be completed in the second quarter. The strong growth, expansion into new markets and the development of our acquisitions will require further development of the organization, both within the core business and in the subsidiaries. To continue to develop our technology and take advantages of the business situation, we have a very ambitious recruitment and growth plan. With 20 machines in order, a stable aftermarket and a positive business situation we are prepared for a continued strong growth in 2015. Mölndal, April 21, 2015 Magnus René, President & CEO The information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published on April 21, 2015 at 08.30 (CET).

WELCOME TO ANNUAL GENERAL MEETING (AGM) IN OPUS GROUP AB (PUBL)

NOTICE OF PARTICIPATION Shareholders wishing to participate in the AGM shall be registered in the Shareholders’ Register held by Euroclear Sweden AB as of Friday May 15, 2015, and have notified the company of their intention to attend by Friday May 15, 2015. Notification of participation at the AGM shall be made through Opus Group’s website, in writing to ”AGM 2015”, Opus Group AB, Att. Peter Stenström, Bäckstensgatan 11D, 431 49 Mölndal or via e-mail to ir@opus.se. When giving notice of participation, the shareholder shall state his or her name, personal ID/corporate registration number, address and telephone number, and the names of the assistants they wish to invite, if any (maximum two). Shareholders who are represented by proxy shall issue a written, dated, Power of Attorney to be enclosed with the notice of participation. A proxy form is available at Opus Group AB (publ)’s website. If the proxy form is issued by a juridical person, a verified copy of the said person’s certificate of registration or other proof of authorization shall be enclosed. The proxy must not be more than one year old, unless a longer period of validity is stated in the proxy, which may not be more than five years. Originals of proxy forms and certificates of registration, if any, should reach Opus Group AB (publ) on Monday May 18, 2015, at the latest. TRUSTEE-REGISTERED SHARES Shareholders with shares registered in the name of a trustee must, in order to be entitled to take part in the AGM, temporarily register their shares in their own names. Such temporary registration must be effected at Euroclear Sweden AB by Friday, May 15, 2015. To ensure that such registration is completed in time, shareholders are advised to notify their trustees to request temporary registration well before this date. PROPOSED AGENDA 1.Opening of the AGM. 2.Election of chairman of the AGM. 3.Drafting and approval of the voting list. 4.Approval of the agenda. 5.Election of two people to approve the minutes together with the chairman. 6.Review as to whether the AGM has been duly convened. 7.Presentation of the annual report, auditors’ report and consolidated accounts and consolidated auditors’ report, along with a presentation of the CEO. 8.Resolutions 1.Resolution to adopt the income statement and balance sheet and the consolidated income statement and the consolidated balance sheet. 2.Resolution to adopt the appropriation of the company’s profits according to the adopted balance sheet. 3.Resolution to adopt the indemnification of the board members and the CEO. 9.Resolution to adopt the number of Board members and deputies, auditors, audit deputies to be elected at the AGM. 10.Determination of remuneration to the Board of Directors and the auditors. 11.Election of Board chairman, Board members, deputies, auditors, deputy auditors and registered public accounting firms. 12.Proposal of the instructions for appointing the members of the nomination committee. 13.Resolution to adopt guidelines for determining salaries and other remuneration to senior executives. 14.Resolution to implement an incentive program (Option program 2015) through a directed issue of options with a following right to subscribe for shares (series 2015/2018). 15.Resolution to authorize the Board to acquire and transfer own shares. 16.Resolution to authorize the Board to decide on new issues of ordinary shares. 17.Other matters. 18.Closing of the AGM. MATTERS TO BE DECIDED Election of chairman of the AGM (point 2) The nomination committee proposes Anders Strid to be appointed as the Chairman of the AGM. Appropriation of the company’s profits (point 8b) The Board proposes that a dividend of SEK 0.09 per share be paid out. The Board proposes the record date for receiving the dividend to be May 25, 2015. If the AGM votes in accordance with the proposal, payment is expected to be made via Euroclear Sweden AB on May 28, 2015. Resolution to adopt the number of Board members and deputies, auditors, deputy auditors to be elected at the Shareholder’s Meeting (point 9) The nominations committee proposes that there be five ordinary Board members and no deputies. The nominations committee proposes that a registered public accounting firm be appointed as auditor. Determination of remuneration to the Board of Directors and the auditors (point 10) The nomination committee proposes a remuneration of SEK 400 000 to the Chairman of the Board of Directors and SEK 175 000 to each other non-employed Board members. The nomination committee further proposes that the remuneration paid for work on the audit committee amounts to SEK 70 000 to the Chairman of the audit committee and SEK 50 000 to the second member of the audit committee. Auditor fees shall be paid against approved account. Election of board members and auditors (point 11) The Nomination Committee proposes re-election of the following Board members Göran Nordlund, Lothar Geilen, Jan Åke Jonsson and Anders Lönnqvist and new election of Heléne Mellquist. The Nomination Committee proposes re-election of Göran Nordlund as Chairman of the Board. Eva-Lotta Kraft has declined re-election. The Nomination Committee proposes that the registered public accounting KPMG AB be elected to act as auditor for a period of one year, with Jan Malm as Authorised Public Accountant. Proposal of the instructions for appointing the members of the nomination committee (point 12) The nomination committee proposes the Shareholder’s Meeting to decide on the following instructions for appointing the members of nomination committee: The proposal implies the following in brief. The nominating committee shall consist of not fewer than five and no more than six members, one of whom shall be the Chairman. The other members shall be appointed by the four largest shareholders in the company measured by voting power on September 30. If a shareholder abstains from appointing a member the right to appoint a member shall transfer to the subsequent largest shareholder by voting power. The Chairman of the nomination committee shall be the member that at its formation represents the largest shareholder(s) by voting power, provided the nomination committee does not unanimously resolve to appoint another member, appointed by a shareholder, chairman of the nomination committee. The company shall publish the composition of the nomination committee through a press release and on the company’s web site. The majority of the members of the nomination committee are to be independent of the company and its executive management. At least one member of the nomination committee is to be independent of the company’s largest shareholder in terms of votes or any group of shareholders that act in concert in the governance of the company. No compensation shall be paid to the members of the nomination committee. Resolution to adopt guidelines for determining salaries and other remuneration to senior executives (point 13) The Board proposes the AGM to decide on the following guidelines for determining salaries and other remuneration to senior executives. The remuneration to senior executives within the Opus Group shall be competitive. The remuneration shall consist of a fixed and a variable part. The variable part shall consist of salary, pension contributions and other benefits such as car benefit. The variable part consists of bonus. The variable part shall be based on the earnings trend or other predetermined measurable goals. The variable component shall as a rule not exceed 30 percent of the fixed salary. The pension contributions shall be competitive and as a rule, premium-based. The Board shall be entitled to deviate from the guidelines if there are special reasons in individual cases. Resolution to implement an incentive program (Option program 2015) through a directed issue of options with a following right to subscribe for shares (series 2015/2018) (point 14) The board of directors propose that the AGM takes a resolution to implement an incentive program (Option program 2015). The Option program entail that the company, at a maximum, issues 5 500 000 options to the wholly-owned subsidiary Opus Bima AB. Opus Bima AB shall have the rights and the obligations to handle the subscription rights in accordance with Option program 2015. The Option program shall complement the previously resolved and ongoing option programs Option program 2012:1 and Option program 2013:1. Bima shall offer the senior executives, others in the management and certain other employees, mainly in Sweden, to acquire options at market value, which will be calculated by using the valuation model Black & Scholes. Bima shall gratuitously offer options to the senior executives, others in the management and certain other employees in the US. The Option program will include approximately 430 employees within the Opus-group and will substantially be divided as following. ·Senior executives and others in the management mainly in Sweden and the US shall be offered approximately 60 percent of the options. ·Certain other employees in Sweden and the US shall be offered the remaining approximately 40 percent of the options. ·Bima shall have the right to hold options in custody in order to transfer them to new employees within the Opus-group. ·The CEO of Opus Group, Magnus Greko, the CEO of Opus Equipment, Jörgen Hentschel, and the Head of Division Car Inspection, Lothar Geilen, has, due to their already large shareholding, decided to refrain from participating in the Option program in favour of other employees. Subscription of the shares shall be made from 1 July 2018 and until 15 August 2018. The subscription price for the shares subscribed for when exercising the options shall correspond to 125 percent of the average share price of the Opus share during a certain measurement period. The subscription price shall be paid in cash or by offset. The Company shall have the right to, but no obligation, at the request of a participant that is unable to pay the subscription price in cash, at market price acquire the number of options that enables the participant to exercise remaining options to subscribe for shares at which the subscription price shall be paid by offset against the claim relating to the sold options. Upon full exercise of the options a maximum of 5 500 000 new shares will be issued, which together with the previously resolved and ongoing option programs will correspond to a dilution of approximately 4.5 percent. The options transferred to employees in Sweden are not expected to give rise to any payroll expenses nor social security costs for the company. The options transferred to the employees in the US will give rise to social security costs if the employee transfer shares subscribed for through exercise of the options within one year from the exercise of the options. In assumption that the employees in the US will transfer 20 percent of the subscribed shares within one year from the exercise of the options, the social security costs will amount to SEK 100 000. In excess of the social charges, the option program will result in additional costs for financial and legal costs amounting to approximately SEK 100 000. The Board invoke the following as to the reason for the deviation from the shareholders’ preferential rights. The Option program contributes to a higher motivation and engagement among the employees and strengthens the ties between the employees and the company. Further, it is the assessment of the board that the Option program will contribute to the possibilities to recruit and retain competent and experienced employees and is expected to increase the employee’s interest for the business and the earnings trend in the company. Overall it is the Board’s assessment that the option program will be useful for both the employees and the company’s shareholders through an increased share value. The Option program has been prepared by the Board in consultation with the corporate governance. Decision to authorize the Board to acquire and transfer own shares (point 15) The Board propose to the AGM to authorize the Board to, prior to the next AGM, take resolution on acquisition of own shares on one or more occasions. Acquisition of own shares may amount to a maximum corresponding to one tenth of the number of shares issued in the company. The repurchase shall be carried out through an acquisition offer directed to all shareholders, or on NASDAQ Stockholm. Repurchase on NASDAQ Stockholm shall be at a price which corresponds to the registered stock exchange price interval (spread) at any given time. Repurchase through an acquisition offer directed to all shareholders can only be done against payment in cash and the acquisition shall be made at a rate corresponding with the registered price interval (spread) at any given time with a maximum divergence of 30 % up. The purpose of the repurchase of own shares is firstly to align the company’s capital structure, give added value to the shareholders and to be able to transfer shares in conjunction with the financing of company acquisitions. The Board also propose that the AGM take resolution to authorize the Board to, prior to the next AGM, decide on transfer of the own shares that the company holds at the time of the transfer decision. Transfer of own shares may be carried out on NASDAQ Stockholm at a price corresponding to the registered price interval (spread) at any given time. Transfer of shares may also be carried out outside NASDAQ Stockholm, with or without deviation from the shareholders’ preferential rights and with or without terms of contribution in kind or right to set-off. Transfer of own shares can accordingly be used as means of payment in relation to company acquisitions on conditions in accordance with the Companies Act’s rules on issue of shares. Such transfer can only be made at a price in cash or value of obtained assets corresponding with the stock market price at the time of the transfer. If the exercise of the authorization to acquire or transfer own shares is combined with the exercise of the authorization to issue new shares (point 16), with the purpose of financing the acquisition of the entire or part of the same acquired company, the number of shares that has been transferred and issued in connection with the acquisition, together can correspond to a maximum of one tenth of the number of shares issued in the company at the time of the authorization to issue new shares. The possibility to deviate from the shareholders’ preferential rights at a transfer of own shares is motivated by the fact that a transfer of shares on NASDAQ Stockholm, or otherwise with deviation from the shareholders’ preferential rights can be done with a major rapidity, flexibility and more cost efficient than by a transfer to the shareholders. If the company’s own shares are transferred for compensation in any other form than cash in relation to an acquisition, the company cannot provide the shareholders the opportunity to exercise its preferential rights. Decision to authorize the Board to decide on new issues of ordinary shares (point 16) The Board proposes that the meeting authorizes the Board to take resolution, on one or more occasions prior to the next AGM, with or without preferential right for the shareholders, on a new share issue corresponding to a dilution effect of maximum ten percent of the share capital. The issue can be carried out as a cash-, in kind- or offset issue. The issue can only be carried out at market value. Deviation from the preferential rights for the shareholders is only possible in relation to an acquisition of a company. The reason for the deviation from the preferential rights for the shareholders is that the company in connection with an acquisition rapidly may need access to cash or to make a payment in kind with the shares of the company. If the exercise of the authorization to issue new shares is combined with the exercise of the authorization to acquire or transfer own shares (point 15), with the purpose of financing the acquisition of the entire or part of the same acquired company, the number of shares that has been transferred and issued in connection with the acquisition, together can correspond to a maximum of one tenth of the number of shares issued in the company at the time of the authorization to issue new shares. SPECIAL MAJORITY REQUIREMENT For a decision relating to point 14 to be valid requires the decision must be supported by shareholders with a minimum of nine-tenths of the voting rights and shares represented at the meeting. For a decision relating to points 15 and 16 to be valid requires the decision must be supported by shareholders with a minimum of two-thirds of the voting rights and shares represented at the meeting. NUMBER OF SHARES AND VOTES There are 286 763 431 shares and votes in the company at the time of the notification of the AGM. All shares are ordinary shares. Currently, the company does not own any of the outstanding shares. AVAILABLE DOCUMENTS The annual report, the auditors’ report, the Board’s statement in accordance with chapter 18, § 4, the auditors’ statement in accordance with chapter 8, § 54 of the Swedish Companies Act, the instructions for appointing the members of the nomination committee and the Boards’ complete proposals for decisions under point 14, 15 and 16 will available for the company’s shareholders as of April 30, 2015 on the company’s office, which address is Bäckstensgatan 11D, 431 49 Mölndal, Sweden. The documentation will also be available at the company’s website www.opus.se. The above documents will be mailed to shareholders upon request. The nomination committee's proposals for the 2015 Annual General Meeting is available on the company website www.opus.se. DISCLOSURES AT THE MEETING The Board and CEO may, at the request of any shareholder at the AGM, and if the Board does not consider it to have a negative impact on the company, provide information about conditions that can affect the assessment of matters on the agenda, conditions that can affect the assessment of the company’s or subsidiaries’ financial situation, or the company’s relationship to other Group companies. Gothenburg in April 2015Opus Group AB (publ)The Board

Ultimate award goes to Hallmarq Veterinary MRI – receives Queen’s Award for Enterprise in TWO categories

Hallmarq Veterinary MRI has received two of the UK’s most prestigious awards for outstanding and sustained business achievement. The company is one of only two companies this year to be awarded two accolades with the Queen’s Award for Enterprise– namely in international trade and innovation. The awards are the highest honours that can be bestowed upon a UK company and the winners are decided upon by Her Majesty the Queen and presented at a reception at Buckingham Palace. The innovation award goes to the equine standing MRI (EQ2) developed by Hallmarq. The EQ2 is a world first and remains the ONLY standing equine MRI. The innovation has completely changed how veterinarians approach equine lameness, making it a low risk procedure and allowing more horses to be diagnosed and treated more effectively than ever before. The international trade award reflects the company’s global success as the EQ2 is now used by vets in 22 countries including Dubai, Japan, Brazil, Australia, Europe and North America, with over 50,000 horses scanned worldwide. The EQ2 was invented and is still manufactured in the UK, but the company has had a truly global perspective from business start-up and the company focus is very much on working with veterinary specialists around the world. It has North American offices in Massachusetts, with further offices due to open in Australasia. Magnetic resonance imaging (MRI) uses radio waves to make pictures of organs and structures inside the body. MRI can show veterinarians both the soft tissues structures and bone while X-rays can only image bone. With complex ligaments and tendons in the horse’s hoof this ability is of special value. As a result of standing MRI, horses need not be anaesthetized to undergo an MRI procedure. Anaesthetic deaths are a significant risk in horses, so the EQ2 means that MRI can be used as a diagnostic tool safely and routinely, not just for high performance race horses but also much loved family ponies too. As MRI has a diagnostic success rate in the region of 90%, the ability of veterinarians to successfully treat all kinds of lameness has changed forever as a result of its use.   Hallmarq CEO Dr Jos Belgrave is also an experienced equine vet, “It’s wonderful for the company and those who work here to receive awards and recognition, especially one as important as a Queen’s Award for Enterprise. Receiving two awards exceeded all our expectations.” He continued, “Hallmarq’s EQ2 innovation has genuinely helped alleviate pain and saved the lives of thousands of horses around the world. That in itself is very rewarding.” The commercial success of EQ2 is due in no small part to the innovative commercial protocols introduced by Hallmarq which see veterinary practices partnering with the company, using a ‘pay as you go’ invoicing model. This win-win model has increased accessibility to MRI as a tool. With a focus on the needs of the vet and the animal at the heart of further innovation, the company’s latest MRI is aimed at companion animals. The high field 1.5 Tesla PetVet system is designed around veterinary requirements in imaging terms – from positioning the animal, to the use of innovative dual coil technology for clearer imaging of hard to view structures. With no need for a purpose built shielded room and with 30% lower ownership costs compared to other high field systems, Hallmarq is set to change the approach to diagnoses for cats and dogs too. 

Clinical Phase II study with NeuroSTAT® for traumatic brain injury passes safety evaluation

The ongoing CHIC study (Copenhagen Head Injury Ciclosporin Study) is an open-label, non-comparative clinical Phase IIa study enrolling a total of 20 patients divided into two different dosage groups, where NeuroVive’s drug candidate NeuroSTAT® is being evaluated for the treatment of patients with traumatic brain injury. The study is being conducted at the Department of Neurosurgery at Rigshospitalet, University of Copenhagen, with MD. Jesper Kelsen as Principal Investigator. The study’s first dosage group of 10 patients has now been treated with NeuroSTAT® at the lower dose, and an interim analysis has been completed by an independent safety committee in order to evaluate the treatment’s safety profile. The analysis includes an evaluation of blood concentrations of cyclosporin A (the active substance in NeuroSTAT®) and changes in intracranial pressure and blood samples collected to analyze possible organ injury. According to the analysis, the low-dose treatment is judged to be safe and the study will now continue as planned with the higher dosage group including 10 additional patients. “We’ve now obtained important safety data on what we’ve designated to be the lower dose of NeuroSTAT® for treating patients with traumatic brain injury. We can now move on to include patients that will be treated with a higher dose. This means that the study has reached an important milestone in the clinical trial program of NeuroSTAT®,” commented NeuroVive’s CEO Mikael Brönnegård. More information about the studyThe primary objective of the CHIC study is to evaluate NeuroSTAT®’s safety and pharmacokinetics in blood and cerebrospinal fluid of patients with severe traumatic brain injury on the basis of two different dosage levels. Secondary explorative measures will be completed to study NeuroSTAT®’s efficacy at the mitochondrial level and to study how different biochemical processes are affected by NeuroSTAT® following traumatic brain injury. In addition to interim analysis, the safety profile of the treatment is evaluated continuously. More information about the study has been published in the public database ClinicalTrials.gov at: https://clinicaltrials.gov/ct2/show/NCT01825044 Current status of NeuroVive’s projects and drug candidates CicloMulsion®NeuroVive’s product CicloMulsion® is the first cyclophilin inhibitor developed for the treatment of reperfusion injury. The product’s potential in the treatment of myocardial infarction is currently being evaluated in a clinical phase III study. The last of a total of 972 patients was enrolled on 16 February 2014. The results of the study are due to be announced in the third quarter 2015 following the completion of the one-year follow-up of all patients and the analysis of the study data. CicloMulsion® will also be evaluated in a number of clinical phase II studies for the treatment of other acute cardiac and kidney injury within the framework of the collaboration with Hospices Civils de Lyon and Skånes University Hospital in Lund, Sweden. NeuroSTAT®NeuroVive is developing NeuroSTAT® for the treatment of patients with moderate or severe traumatic brain injury. NeuroSTAT® is currently being evaluated in a clinical phase IIa study at Copenhagen University Hospital. The study focuses on safety and pharmacokinetics, and 10 of 20 planned patients have been enrolled so far. A phase III study is currently being planned and designed. NeuroVive has secured orphan drug designation for NeuroSTAT® for moderate and severe traumatic brain injury in the US and EU, which implies market exclusivity for seven years in the US and ten years in the EU, from the date NeuroVive obtains market authorization. NVP019NVP019 is NeuroVive’s primary drug candidate in the company’s new portfolio of potent cyclophilin inhibitors belonging to a family of molecules known as Sangamides based on a new and unique polyketide engineering technology. NVP019 is being developed as the next generation cyclophilin inhibitor for the treatment of reperfusion injury in myocardial infarct, but also for other acute conditions where general protection of vital organs is central to the progression of the disease. An intravenous formulation will be evaluated for this purpose in collaboration with external parties such as Hospices Civils de Lyon within the framework of the OPeRa program. NVP018NVP018 is an oral formulation based on the same active substance as NVP019. It has been developed for treatment of Hepatitis B and was outlicensed to OnCore Biopharma, Inc. (www.oncorebiopharma.com) in September 2014. OnCore Biopharma has designated the drug candidate OCB030. Other productsMore information about all products developed by NeuroVive can be found at http://www.neurovive.se/index.php/en/research-development/research-overview About NeuroViveNeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (myocardial infarct) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include development of treatments against brain injury in stroke patients, and drug substances for cellular protection and treatment of mitochondrial disorders causing energy deficiency. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden. For Investor Relations and media questions, please contact:Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.seIt is also possible to arrange an interview with NeuroVive’s CEO Mikael Brönnegård or COO Jan Nilsson at the above contact. NeuroVive Pharmaceutical AB (publ)Medicon Village, SE-223 81 Lund, Sweden, Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48info@neurovive.se, www.neurovive.se NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 21 April 2015, at 9.45 a.m. CET.

Interim report January - March 2015

Kai Wärn, President and CEO:"Since January 1, Husqvarna Group operates under a new brand-driven divisional structure. The new organization shall be seen as a proactive measure to position Husqvarna Group for the next phase 2016 and beyond, with a stronger focus on profitable growth. In 2015 however, the main focus will remain on operating margin recovery through the Accelerated Improvement Program (AIP). Overall, the year has started well for us. Group operating income increased by 22% to SEK 1,112m (908), despite a currency adjusted sales decline of -3%. The corresponding operating margin rose to 10.2% (9.4). Even if total sales declined, the development in terms of divisional mix was positive. Sales increased 9% in both of our higher margin forest and garden divisions Husqvarna and Gardena. Consumer Brands’ sales were down by -21% predominantly reflecting a late start of the season due to another cold winter in the U.S., and our ambition to prioritize value before revenue. Construction was off to a slow start, mainly due to external reasons, but sales gradually improved and ended at an increase of 2% but with a significantly higher run-rate in March. AIP continues to deliver according to plan and the trend of improving gross and operating margins for the Group remains. Margins were positively affected by continued impact from the two main components in our improvement program; Operational Excellence driven cost reductions and sales growth in our product leadership areas - the latter having a favorable impact on the mix. Some of the progress was offset by unfavorable volume impact due to the lower sales in Consumer Brands. On the other hand, income for the Group was supported by a positive impact from changes in exchange rates, as currency hedges offset most of the negative transaction effects. The recent currency movements have helped us short term, but the longer-term impact, mainly referring to the strengthening of the USD, is expected to have a negative impact. So whereas operating income and margin recovery have been solid since the launch of the AIP program, additional improvement areas to balance the negative currency impact have been identified, such as indirect material and logistics as well as capacity and efficiency measures.” First quarter, January - March · Net sales increased by 13% to SEK 10,928m (9,685). Adjusted for exchange rate effects, net sales decreased -3%.- Growth for Husqvarna, Gardena and Construction, while Consumer Brands declined substantially. · Operating income rose 22% to SEK 1,112m (908).- Operational Excellence cost reductions and favorable divisional mix. · Positive short-term impact from changes in exchange rates amounting to SEK 107m. · Earnings per share increased to SEK 1.37 (1.08). · Operating cash flow amounted to SEK -2,410m (-1,969). Telephone conferenceA telephone conference, hosted by Kai Wärn, President and CEO, and Jan Ytterberg, CFO, will be held at 13:45 CET on April 21, 2015. To participate by phone, please dial +46 (0) 8 5052 0110 (Sweden) or +44 (0)20 7162 0077 (UK) ten minutes prior to the start of the conference. The conference call will also be audio cast live on www.husqvarnagroup.com/ir (http://www.husqvarna.com/ir). A replay will be available at www.husqvarnagroup.com/ir (http://www.husqvarna.com/ir) later the same day.

Recipharm is commencing negotiations with LIDDS on large-scale manufacture of Liproca® Depot

In a joint letter of intent the companies have explained their intention to initiate collaboration regarding scale-up, manufacture and quality assurance of LIDDS’ pharmaceutical products. Such a collaboration will initially focus on Liproca®Depot, a targeted treatment for prostate cancer that is currently in Phase II, but it may also include other products based on LIDDS’ unique technology platform. The  letter of intent follows a so-called feasibility study performed by Recipharm. The results of this study confirm the possibility of developing a process for manufacture that ensures a high-quality end product. “Collaboration with a manufacturing partner as renowned as Recipharm increases the power of attraction of our prostate-cancer product Liproca®Depot. A high-quality and cost-effective manufacturing process increases the chances of in the future being able to offer better treatment to patients with prostate cancer,” says Monica Wallter, LIDDS’ CEO. “There is great potential in LIDDS’ technology platform for development of new treatments for diseases where  local administration is desirable. We look forward to contributing with our technical expertise in the field of manufacture, so that cancer patients can in future be offered treatments associated with fewer side effects,” says Maria Lundberg General Manager Recipharm Pharmaceutical Development. Contact informationMaria Lundberg, General Manager Recipharm Pharmaceutical Development, maria.lundberg@recipharm.com, + 46 8 6025 273Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, monica.wallter@liddspharma.com For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: t.jervis@defacto.com or a.heeley@defacto.comTel: +44 (0) 207 861 3019/3043 About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com About LIDDSLIDDS’ goal is to develop pharmaceutical products with fewer side effects for various forms of cancer. The company’s most advanced project – the prostate‑cancer product Liproca® Depot – has already displayed very good results in clinical trials. LIDDS’ unique drug-delivery technology releases drugs locally, close to the tumour, so as to reduce the side effects and the number of doses. The fact that LIDDS technology can utilise pharmaceutical substances already approved by authorities reduces the risk of development and the time and cost necessary to achieve marketing approval.   For further information visit www.lidds.se

Eureka Entertainment to release A LETTER TO THREE WIVES

Eureka! Entertainment have announced the release of A LETTER TO THREE WIVES, the classic Oscar nominated Hollywood comedy drama, written and directed by Joseph L. Mankiewicz (the director of All About Eve) who won the Oscars for Best Director and Best Screenplay for his work on the film.  Starring Jeanne Crain, Linda Darnell, Ann Sothern as the ‘three wives’ who each receive a letter from their absent friend informing them that she has run off with one of their husbands, and featuring an early turn from Kirk Douglas.  A LETTER TO THREE WIVES will be released on Blu-ray in a Dual Format (Blu-ray & DVD) edition as part of Eureka’s award-winning The Masters of Cinema Series on 29 June 2015. A stunning romantic drama from writer-director Joseph L. Mankiewicz (All About Eve, The Barefoot Contessa), A Letter to Three Wives explores the domestic travails of three couples and the woman that brings them to the brink of crisis. The letter of the title is written with a poisonous pen: the three women (portrayed by Jeanne Crain, Linda Darnell, and Ann Sothern) receive a note stating that one of their husbands has run off with a woman named Addie Ross – which husband in particular, however, remains unmentioned, though each husband had their own affinity for Ross. And so amid the women’s mounting anxiety commences a series of flashbacks, each telling the story of how the three individual marriages had come in their own way to be so strained at the present... A spectacular success at the time of its release, A Letter to Three Wives was nominated for the Best Picture Oscar, and earned Mankiewicz the Academy Awards for both Best Director and Best Screenplay. The Masters of Cinema Series is proud to present A Letter to Three Wives in a special Dual Format edition that includes the film on Blu-ray for the first time in the UK. SPECIAL DUAL FORMAT (BLU-RAY + DVD) EDITION featuring: · Gorgeous 1080p presentation of the film on Blu-ray · Optional English subtitles for the deaf and hard-of-hearing · Feature-length audio commentary with Mankiewicz biographer Kenneth Geist, film historian Cheryl Lower, and actor Christopher Mankiewicz, the director’s son · Fox Movietone newsreel covering the Academy Awards ceremony · 36-page booklet containing essays, interview material, and rare archival imagery · Original Theatrical Trailer NOTES FOR EDITORS: DETAILS: · Label: Eureka · Dual Format Cat. No.| EKA70187 · Dual Format Barcode| 5060000701876 · Dual Format SRP| £19.99 · Release Date| 29 June 2015 · Certificate| U · Run Time| 103 min. · OAR| 1.37:1 OAR · Picture| Black & White · Genre| Drama / Romance · Director| Joseph L. MANKIEWICZ · Year| 1949 · Country| USA · Language| English · Subtitles| English (Optional)

California B&Bs Help Electric Vehicle Owners Go the Extra Mile with EV Charging Stations

Sacramento, CA [April 21, 2015]--Taking a scenic drive in an electric vehicle up a High Sierra pass, through the redwoods, or along a remote stretch of California coastline is now possible thanks to a growing number of California boutique hotels and bed and breakfast inns that have installed electric vehicle charging stations.  Just last month, Stephanie McCaffrey, the owner of the McCaffrey House Bed & Breakfast Inn (https://www.cabbi.com/inn/McCaffrey-House-Bed-Breakfast-Inn/), had two electric vehicle charging stations installed at her inn in Twain Harte.  They include a Tesla High Power Wall Connector for Tesla Model S owners and a Clipper Creek HCS-40, which charges other all plug-in vehicles including Nissan Leaf, BMW i3, BMW i8, Chevy Volt, Ford Focus Electric, Fiat 500e, Volkswagen e-Golf, Ford C-Max, and Ford Fusion Energi.  “We’re the only charging station on the Highway 108 corridor,” says McCaffrey.  “We’ve already had drivers stop by to charge up, and our first overnight guest with a Tesla is coming up within a couple weeks. We’re very excited.” The McCaffery House Bed & Breakfast Inn joins 17 other California Association of Boutique and Breakfast Inns (CABBI) member inns in far-flung towns across the state with electric vehicle charging stations.  At all of the inns, charging is free to guests staying overnight or dining at the respective inn; non-guests are typically charged a nominal fee of $3 to $5.  Other CABBI-member inns with electric vehicle charging stations in the Sierras include Dunbar House, 1880 (https://www.cabbi.com/inn/Dunbar-House-1880/) in Murphys near State Route 4 leading up to the Ebbetts Pass Scenic Byway and Groveland Hotel (https://www.cabbi.com/inn/Groveland-Hotel-at-Yosemite-National-Park/) off of Highway 120 on the way to Yosemite National Park.  In the Central Valley, the Inn at Locke House (https://www.cabbi.com/inn/Inn-At-Locke-House/) in Lodi off of State Route 88 (the Carson Pass Highway) has a Tesla charging station.  In Sonoma’s wine country, there are four inns with charging stations: Case Ranch Inn (https://www.cabbi.com/inn/Case-Ranch-Inn-Bed-Breakfast/), Farmhouse Inn (https://www.cabbi.com/inn/Farmhouse-Inn/), Gables Wine Country Inn (https://www.cabbi.com/inn/Gables-Wine-Country-Inn/) and Inn at Occidental (https://www.cabbi.com/inn/Inn-at-Occidental-of-Sonoma-Wine-Country/).  The Inn on Randolph (http://www.innonrandolph.com/) in downtown Napa also has charging stations.  In the rural town of Upper Lake in Lake County, the historic Tallman Hotel (https://www.cabbi.com/inn/Tallman-Hotel/) was one of the first inns in the state to install an electric vehicle charging station.  Heading up the Mendocino Coast along Highway 1, Sea Ranch Lodge (https://www.cabbi.com/inn/Sea-Ranch-Lodge/), Brewery Gulch Inn (https://www.cabbi.com/inn/Brewery-Gulch-Inn) and Stanford Inn by the Sea (https://www.cabbi.com/inn/Stanford-Inn-by-the-Sea/) all have charging stations. On the redwood coast, in the Victorian village of Ferndale, the Victorian Inn (https://www.cabbi.com/inn/Victorian-Inn/) has a Tesla charging station to fuel drives through Avenue of the Giants.  South of the legendary Highway 1 drive along the Big Sur coastline, there are two inns in Cambria with charging stations: El Colibri Boutique Hotel & Spa (https://www.cabbi.com/inn/El-Colibri-Boutique-Hotel-Spa/) and Blue Dolphin Inn (https://www.cabbi.com/inn/Blue-Dolphin-Inn/).  Just a little further south in Cayucos, On the Beach Bed & Breakfast (https://www.cabbi.com/inn/On-The-Beach-B-B/) offers two Tesla High Power Wall Connectors and one Clipper Creek charger. In Santa Barbara wine country, the Santa Ynez Inn (https://www.cabbi.com/inn/Santa-Ynez-Inn/) also now offers a Tesla charging station. For a map of CABBI-member inns along California’s electric vehicle trail, visit: http://tinyurl.com/oz3psln.  More information about each of the inns listed above is available at https://www.CABBI.com. ### Media Contact: Ranee Ruble, ranee@papermooncreative.net or 503-788-3938

Cokie and Steve Roberts Highlight Five Honorary Degree Recipients for Montgomery College Commencement, May 22

-- Longtime DC Journalists Will Also Deliver Commencement Address.Montgomery College will recognize the class of 2015 in commencement ceremonies May 22 at 10 a.m. on the Rockville Campus. Graduates from the College’s three campuses in Montgomery County, Md., Germantown, Rockville and Takoma Park/Silver Spring, along with apprenticeship graduates in the Workforce Development and Continuing Education programs will be honored. In addition, the Board of Trustees will pay tribute to community leaders and College benefactors. Honorary degrees will be presented to Eliot Pfanstiehl, CEO and founder of Strathmore Hall Foundation, Inc; C. Marie Taylor, executive director of the Community Foundation of Montgomery County; Dr. Michael Lin, former chair of the Board of Trustees of Montgomery College and biomedical research scientist; and commencement speakers, journalists Cokie and Steve Roberts.Cokie Roberts is a political commentator for ABC News, providing analysis for all network news programming. Roberts also contributes political analysis for National Public Radio. In her more than 40 years in broadcasting, she has won countless awards, including three Emmys. She was cited by the American Women in Radio and Television as one of the 50 greatest women in the history of broadcasting. In addition to her appearances on the airwaves, Roberts, along with her husband, Steven V. Roberts, writes a weekly column syndicated in newspapers around the country.Steve Roberts has covered some of the major events of the last 50 years, including 12 presidential election campaigns. He spent 25 years with the New York Times serving as both the Congressional and White House correspondent. He was also a senior writer at U.S. News for seven years, specializing in national politics and foreign policy. Roberts and his wife, Cokie, write a nationally-syndicated newspaper column. In addition, Roberts is the Shapiro Professor of Media and Public Affairs at George Washington University (GW). His 2009 book From Every End of This Earth, the story of 13 immigrant families in America, started in the feature writing course he teaches at GW and is dedicated to his students.Dr. Michael Lin emigrated from Taiwan, China to the U.S. more than 40 years ago. He received his Ph.D. degree in biochemistry from Medical College of Georgia and worked as a biomedical research scientist at the National Institutes of Health for more than 30 years. He contributed to a Nobel Prize and his work was described in his mentor’s Nobel lecture. He is currently a member of Maryland Council for New Americans, the former chair of the Board of Trustees of Montgomery College, and member of the Committee of 100. He also serves on the Montgomery College Life Sciences Park Foundation Board. Over the years, Dr. Lin has assumed many leadership roles within the Organization of Chinese Americans (OCA), including serving as the national executive director.Eliot Pfanstiehl is the CEO and founder of Strathmore Hall Foundation, Inc., which operates and presents programming at Strathmore, a multi-disciplinary arts center, including the Music Center and the Mansion at Strathmore, in Montgomery County, Maryland. Mr. Pfanstiehl led the successful effort to build the world-class Music Center at Strathmore which opened in 2005. Mr. Pfanstiehl has been a founder, president or chair of Montgomery County Arts Council, the Round House Theatre, the League of Washington Theatres and Strathmore. He has served on numerous other boards including the Friends of the Kennedy Center, Black Rock Arts Center, Cultural Alliance of Greater Washington, and the Maryland Association of Non-profit Organizations. Mr. Pfanstiehl is the founding president of Maryland Leadership Workshops and has led over 300 board and strategic planning retreats for a range of non-profit civic, arts and social service organizations, government agencies and businesses.C. Marie Taylor is the executive director of the Community Foundation of Montgomery County. She has been an exceptional partner with Montgomery College through philanthropy, advocacy initiatives such as health insurance for students, and projects such as the African American Youth Report. She has also served as executive director of Interfaith Works and had a long career at Food & Friends, a nonprofit organization providing meals and counseling to individuals living with HIV/AIDS, cancer, or other life-challenging illnesses. She holds a BA in human relations and a MBA in nonprofit management from Trinity University.###Montgomery College is a public, open admissions community college with campuses in Germantown, Rockville, and Takoma Park/Silver Spring, plus workforce development/continuing education centers and off-site programs throughout Montgomery County, Md. The College serves nearly 60,000 students a year, through both credit and noncredit programs, in more than 130 areas of study.

Annual General Meeting at JM AB

The Annual General Meeting resolved to pay a dividend of SEK 8 per share. The record date for the dividend is Thursday, April 23, 2015. The dividend is expected to be sent by Euroclear Sweden AB on Tuesday, April 28, 2015. Board of Directors and remuneration The Annual General Meeting resolved that there should be eight Directors. Lars Lundquist was reelected Chairman of the Board. Kaj-Gustaf Bergh, Johan Bergman, Anders Narvinger, Eva Nygren, Kia Orback Pettersson, Johan Skoglund and Åsa Söderström Jerring were reelected to the Board of Directors. The Chairman will be paid SEK 760,000 for work on the Board, and Directors who are not employed by the Company will be paid SEK 320,000. Committee fees Directors who are not employed by the Company will receive remuneration for work on committees as follows: Chairperson of the Audit Committee: SEK 120,000 Director on the Compensation Committee: SEK 90,000 Chairperson of the Compensation Committee: SEK 60,000 Director on the Compensation Committee: SEK 60,000 Chairperson of the Investment Committee: SEK 80,000 Director on the Investment Committee: SEK 60,000 The total fee for the seven paid Directors amounts to SEK 3,300,000, including remuneration for committee work, which entails an increase of SEK 80,000. Election of auditors The Annual General Meeting resolved to elect Ernst & Young as the audit company. In accordance with the Swedish Companies Act, the term of service runs until the end of the 2016 Annual General Meeting. Nomination Committee Approval of the instructions for the Nomination Committee that were adopted at the 2014 Annual General Meeting. The instructions for the Nomination Committee are available on JM AB's website, www.jm.se. Guidelines for salaries and other remuneration The Annual General Meeting approved the proposed guidelines for salaries and other remuneration to senior executives. Compensation to the CEO and other senior executives will consist of a fixed component, short- and long-term variable components, pension benefits and other benefits. “Other senior executives” refers to the Executive Management. Total compensation must be at market rates and competitive in the labor market in which the executive works. Convertible Program The Annual General Meeting resolved that JM would raise a debenture loan with a maximum nominal value of SEK 160,000,000 by issuing a maximum of 500,000 convertible debentures aimed at all employees in Sweden. The convertibles' issue price shall correspond to the nominal amount. It will be possible to convert each convertible to an ordinary share, at a conversion price equivalent to 125 percent of the latest noted average price paid for ordinary shares in JM on the official exchange list of the NASDAQ Stockholm AB for the period from April 22, 2015 to May 6, 2015. The Annual General Meeting resolved that the terms will be in accordance with the proposal. Buy-back The Annual General Meeting resolved to authorize the Board to decide on the acquisition of ordinary shares in JM AB on a regulated market. The acquisition of ordinary shares in JM AB may only occur on NASDAQ Stockholm. The authorization may be utilized on one or more occasions, although no longer than up until the 2016 Annual General Meeting. The number of shares that may be acquired is limited such that the Company's holdings do not at any point in time exceed ten (10) percent of all the Company's ordinary shares. The acquisition of ordinary shares in JM AB on NASDAQ Stockholm may only occur at a price within the NASDAQ Stockholm current spread, which refers to the spread between the highest bid price and the lowest ask price. The objective of empowering the Board of Directors is to give it greater freedom of action and the possibility to adjust the Company's capital structure on a continuous basis. Decrease of share capital The Annual General Meeting resolved to decrease the share capital by SEK 2,040,554 through the elimination of 2,040,554 ordinary shares without repayment to the shareholders. At present, the Company holds a total of 2,040,554 of its own ordinary shares. The ordinary shares were acquired for the purpose of adjusting the Company’s capital structure. The reduction in the share capital shall be allocated to unrestricted equity. The Annual General Meeting's resolution to decrease the share capital in accordance with that set out above may not be effected without authorization from the Swedish Companies Registration Office or, in the event of a dispute, a general court of law.

Bulletin from the Annual General Meeting of Husqvarna AB (publ)

Adoption of the Income Statements and Balance Sheets, dividend and discharge of liability The Income Statements and Balance Sheets were adopted, together with the Board of Directors’ proposal for dealing with the Company’s profit. The dividend was set at SEK 1.65 per share to be paid in two installments, firstly SEK 0.55 per share with Thursday, April 23, 2015 as the first record day, secondly SEK 1.10 per share with Friday October 23, 2015 as the second record day. The estimated dates for payment are Tuesday, April 28, 2015 and Wednesday, October 28, 2015. The Board of Directors and the Presidents were discharged from liability for the financial year 2014. Board of Directors and remuneration to the Directors and the Auditors The Nomination Committee’s proposal that the Board of Directors shall comprise eight Board members to be elected by the AGM, and no deputies, was adopted. Magdalena Gerger, Tom Johnstone, Ulla Litzén, Katarina Martinson, Daniel Nodhäll, David Lumley, Lars Pettersson and Kai Wärn were re-elected. Lars Westerberg declined re-election. Tom Johnstone was elected Chairman of the Board. The AGM approved the Nomination Committee’s proposal regarding remuneration to the Board of SEK 5,260,000 in total, whereof SEK 1,725,000 to the Chairman of the Board, and SEK 500,000 to each of the Directors elected by the AGM and not employed by the Company. The Chairman of the Audit Committee shall receive SEK 175,000 and the two members shall receive SEK 80,000 each. The Chairman of the Remuneration Committee shall receive SEK 100,000 and the two members SEK 50,000 each. The Auditor's fee shall be paid on the basis of approved invoices. Principles for remuneration and long-term incentive program The AGM approved the Board of Directors' proposal for principles of remuneration to Husqvarna Group Management. Furthermore, the AGM approved the Board of Director's proposal for a performance based long-term incentive program for 2015, LTI 2015. Re-purchase and transfers of own shares The AGM authorized the Board of Directors to, on one or more occasions during the period up until the next AGM, approve re-purchase of B-shares, conditioned upon that the Company’s holding does not at any time exceed 1% of the total number of issued shares in the Company. Shares shall be purchased on NASDAQ Stockholm at a price within the share-price spread registered at the time. In addition, the AGM authorized the Board of Directors to on one or more occasions during the period up to the next AGM, sell the Company’s own B-shares on NASDAQ Stockholm. Shares may only be sold on NASDAQ Stockholm for cash at a price within the share-price interval registered at that time. The AGM further resolved to authorize the Board of Directors to, on one or more occasions, direct the Company to enter one or more equity swap agreements with a third party, on terms and conditions in accordance with market practice. The purpose of the authorizations to re-purchase and sell shares; and to enter into equity swap agreements is to hedge the Company’s undertakings (including social costs) for the Company’s incentive programs and to continuously adapt the number of shares held for this reason. Authorization for new share issue The AGM authorized the Board to approve the issue of not more than approximately 57.6 million new B-shares against consideration in kind, on one or more occasions during the period up to the AGM in 2016. The price for the new shares shall be based on the market price of the Husqvarna B-share. The purpose of the authorization is to facilitate acquisitions for which payment will be made in own shares. Nomination Committee At the AGM in 2013 it was decided that, until the AGM resolves otherwise, the Company shall have a Nomination Committee consisting of five members. The members shall comprise one representative of each of the four largest shareholders in the Company in terms of the number of known vote rights held as of the last banking day of August, and who have expressed a wish to participate in the nomination committee work, together with the Chairman of the Board of Directors.  The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 19.15 on April 21, 2015.

INTERIM REPORT JANUARY-MARCH 2015

· Consolidated net revenues for the first quarter of 2015 amounted to SEK 1,370 M (1,204). · Operating earnings (EBIT) amounted to SEK 339 M (283). The operating earnings include revaluations of Purchased Debt portfolios amounting to a negative SEK 7 M (–10). Excluding revaluations, the operating margin was 25 percent (24). · Net earnings for the quarter amounted to SEK 244 M (184) and earnings per share were SEK 3.27 (2.35). · Cash flow from operating activities amounted to SEK 483 M (530). · The carrying value of purchased debt has increased by 12 percent compared with the first quarter of 2014. Disbursements for investments in purchased debt during the quarter amounted to SEK 469 M (619). Comment by President and CEO Lars Wollung Intrum Justitia’s development was favorable in the first quarter of 2015. Compared with the equivalent period in 2014, and adjusted for currency effects and the revaluation of portfolios, consolidated revenues rose by 7 percent and operating earnings by 12 percent. Earnings per share rose by 39 percent compared with the first quarter of 2014. In our regions, mainly Northern Europe and Central Europe experienced favorable development as a result of increased investment levels in Purchased Debt in previous years and improved margins in Credit Management. The corporate acquisitions made in 2014 in the Czech Republic, France and Denmark have also developed well. In our service lines, both Financial Services and Credit Management reported improved earnings. In Credit Management, growth and margins are increasing well through acquisitions and improved operational efficiency. In Financial Services, the return on Purchased Debt remains excellent at 19 percent. The carrying value of Purchased Debt rose by 12 percent compared with the corresponding period in 2014 and the investments level for the quarter amounted to SEK 469 M. The supply of past-due consumer receivables is generally good, although there is considerable price competition in most markets. In the first quarter, we also continued to develop our operations in financial services before invoices mature. In the first quarter, we established Avarda, a joint venture with the Swedish company TF Bank, to offer payment and financing solutions to e-traders in the Nordic region. We also launched a similar service for the Swiss market during the quarter. During 2015, we will continue to focus strongly on generating value for our customers. By continuously developing Intrum Justitia’s offering of Credit Management and Financial Services, we are contributing to positive development for our customers through lower credit losses, improved cash flow and increased focus on their core operations. Our internal focus on continuous improvement is continuing and we are constantly monitoring a very large number of change projects in most of the countries in which we operate. I therefore take a positive view of Intrum Justitia’s opportunities for continued good development with profitable growth over the next few years. Presentation of the year-end report The interim report and presentation material are available at www.intrum.com/Investor-Relations/. President & CEO Lars Wollung and Chief Financial Officer Erik Forsberg will comment on the report at a teleconference today, starting at 9:00 a.m. CET. The presentation can be followed at www.intrum.com and/or www.financialhearings.com. To participate by phone, call +46 (0)8 566 426 63 (SE) or +44 (0) 20 342 814 06 (UK). For further information, please contact Lars Wollung, President & CEO Intrum Justitia AB (publ) Tel: +46 (0)8-546 10 202Erik Forsberg, Chief Financial Officer, Tel.: +46 (0)8-546 10 202

Nordic Nanovector ASA - Stabilisation notice and exercise of over-allotment option, total gross proceeds from IPO increase to NOK 575 million

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT. Nordic Nanovector ASA - Stabilisation notice and exercise of over-allotment option, total gross proceeds from IPO increase to NOK 575 million Oslo, 22 April 2015: Reference is made to the announcement issued by Nordic Nanovector ASA (“Nordic Nanovector” or the “Company”, ticker code “NANO”) and ABG Sundal Collier Norge ASA (the "Stabilisation Manager") on 20 March 2015 regarding potential stabilisation activities in respect of the shares in Nordic Nanovector in the period from 23 March 2015 to and including 21 April 2015 (the "Stabilisation Period") in connection with Nordic Nanovector’s initial public offering (the "Offering"). The Stabilisation Manager hereby gives notice that no stabilisation purchases have been undertaken in relation to the shares in Nordic Nanovector and that no further stabilisation activities will be carried out.The Stabilisation Manager has exercised the option to purchase from the Company 2,343,750 new shares in the Company (the "Over-Allotment Option"), equalling 15% of the aggregate number of new shares allocated in the Offering, at a price per share of NOK 32, which is equal to the offer price in the Offering. The 2,343,750 shares will be delivered to HealthCap VI L.P. from whom the same number of shares were borrowed in connection with the over-allotment and stabilisation activities in the Offering. After the issuance of the shares in connection with the exercise of the Over-Allotment Option, the Company will have 44,519,041 shares in issue and will receive NOK 75 million in additional proceeds from the Offering and accordingly, total gross proceeds from the Offering increases to NOK 575 million.  For further queries, please contact: ABG Sundal Collier Norge ASA+47 22 01 60 00 About Nordic NanovectorNordic Nanovector is a biotech company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radio-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of Non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin™ comprises a tumor-seeking anti-CD37 antibody conjugated to low intensity radionuclide (Lutetium 177). It has shown promising efficacy in Phase 1 studies in a difficult-to-treat NHL patient population and as well as a very favourable tolerability. Betalutin™ is fast advancing through clinical development and with first approval anticipated in 2018. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialization of Betalutin™ in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat a number of select cancer indications. Further information about the Company can be found at www.nordicnanovector.com IMPORTANT INFORMATION United StatesThese materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the “Shares”) of Nordic Nanovector ASA (the “Company”) in the United States, Norway or any other jurisdiction. The Shares of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”). The Shares of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to “qualified institutional buyers” as defined in Rule 144A under the U.S. Securities Act. European Economic AreaAny offering of securities will be made by means of a prospectus to be published that may be obtained from the issuer or selling security holder, once published, and that will contain detailed information about the Company and its management, as well as financial statements.These materials are an advertisement and not a prospectus for the purposes of Directive 2003/71/EC, as amended (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not subscribe for any securities referred to in these materials except on the basis of information contained in the prospectus.In any EEA Member State other than Norway (from the time the prospectus has been approved by the Financial Supervisory Authority of Norway, in its capacity as the competent authority in Norway, and published in accordance with the Prospectus Directive as implemented in Norway) that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at “qualified investors” in that Member State within the meaning of Article 2(1)(e) of the Prospectus Directive (“Qualified Investors”), i.e., only to investors to whom an offer of securities may be made without the requirement for the Company to publish a prospectus pursuant to Article 3 of the Prospectus Directive in such EEA Member State. United KingdomIn the United Kingdom, these materials are only being distributed to and are only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as “Relevant Persons”). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Volvo Group – the first quarter 2015

In the first quarter of 2015 the effects of the Volvo Group’s strategic efficiency-improvement program continued to generate results. In several areas of the Group margins were improved, despite a negative market mix with significantly lower volumes in Brazil for trucks and in China for construction equipment. · In the first quarter net sales amounted to SEK 74.8 billion (65.6). Adjusted for currency movements and acquired and divested units sales decreased by 1%. · Operating income amounted to SEK 7,066 M (2,588) excluding restructuring charges of SEK 229 M (318). Operating income includes a positive impact of SEK 2,471 M from the sale of shares in Eicher Motors Limited. Currency exchange rates had a positive impact of SEK 1,282 M. · Operating income excluding restructuring charges and the capital gain from the sale of shares amounted to SEK 4,595 M (2,588), corresponding to an operating margin of 6.1% (3.9). · Operating cash flow in the Industrial Operations amounted to SEK –1.7 billion (–9.0). · Net financial debt in the Industrial Operations amounted to 23% of equity. · Truck order intake increased by 3% while order intake of construction equipment decreased by 24%. · Acquisition of 45% of Dongfeng Commercial Vehicles completed. Press and Analysts Conference 09.00 AM CET. An on-line presentation of the report, followed by a question-and-answer session will be webcast at 09.00 CEST. Conference call for investors and analysts 3.00 PM CEST. Aktiebolaget Volvo Contacts Investor Relations:(publ) 556012-5790Investor Christer Johansson         +46 31 66 13 34Relations, VHQSE-405 08 Patrik Stenberg                 +46 31 66 13 36Göteborg, SwedenTel +46 31 66 00 Anders Christensson       +46 31 66 11 9100 John Hartwell                   +1 201 252 8844www.volvogroup.com

Martin Lundstedt appointed President and CEO of the Volvo Group

“After three years of focus on product renewal, internal efficiency and restructuring, the Volvo Group is gradually entering a new phase with an intensified focus on growth and increased profitability. This will be achieved by further building on our leading brands, strong assets and engaged and skilled employees all over the world“, says Carl-Henric Svanberg, Chairman of the Board of AB Volvo. “Martin Lundstedt has 25 years of experience from development, production and sales within the commercial vehicle industry. He is also known for his winning leadership style.” As of April 22, 2015, and until Martin Lundstedt assumes his new position, Jan Gurander, the Group Chief Financial Officer will be acting President and Chief Executive Officer of Volvo. Martin Lundstedt will replace Olof Persson who has led the Group for almost four years. “Olof Persson has with energy and determination carried out an extensive change of the Volvo Group,” says Carl-Henric Svanberg. “He has focused Volvo on commercial vehicles and sold unrelated businesses and assets to a value of over SEK 20 billion. He introduced a functional organization and paved the way for cost savings of SEK 10 billion. He also concluded the agreement with one of China’s largest truck manufacturers, Dongfeng and led the company during the largest product renewal in the Group’s history. Today the Volvo Group is considerably better positioned to compete for leadership in our industry.” Martin Lundstedt has spent his career at Scania. He joined in 1992 as a trainee after obtaining an MSc in Industrial Management and Technology. He has held a number of executive positions. Curriculum Vitae – Martin Lundstedt Born in 1967 MSc in Industrial Management and Technology 1995 Project leader Scania do Brasil 1996 Manager Industrial Engineering, Scania Engine Production 1997 Production Manager Scania Engine Production 1999 Head of Basic Engine Development 2001 Managing Director of Scania Production, Angers France 2005 Head of Product Marketing and member of the Executive Team 2006 Head of trucks 2007 Head of Franchise and Factory Sales 2012 President and CEO of the Scania Group Married, two children Press conference Today, at April 22, 2015, at 09.00 a.m. there will be a press conference with Carl-Henric Svanberg, Chairman of the Board of AB Volvo. The Volvo Group Chief Financial Officer Jan Gurander will present the result of the first quarter 2015. The press conference will be held at Tändstickspalatset, V Trädgårdsgatan 15 in Stockholm. Follow the press conference at www.volvogroup.com and www.volvokoncernen.se April 22, 2015 Journalists who would like further information, please contact: Kina Wileke +46 (0)31323 7229 or +46 (0)765-537229.  

INCREASED PROFITS AND RECORD REVENUES

“We increase our net sales and profits, and improve our margin compared to the same period last year. Our cash flow continues to be strong. As we now turn 20 and leave our teen years behind us, we do it with the sensation that working with what we do has never been more exciting,” says Lars Stugemo, President and CEO at HiQ. During the first quarter of the year, HiQ wins new framework agreements and assignments with forward clients, and is named one of Sweden’s Career Companies. This authenticates the view of HiQ as an attractive employer. “We see simplicity as the innovation of our time. As digitalisation and mobility claim a place in all industries, we become an evident innovation partner for our clients. New business models are taking form, and the possibilities to simplify people’s lives through technology are never-ending,” Lars Stugemo concludes. HiQ’s President and CEO, Lars Stugemo, presents the report today, Wednesday 22 April at 09:00 CET, at HiQ’s head office (Regeringsgatan 20) in Stockholm. The report can be ordered by phone (+46 8 588 90 000) or downloaded from www.hiq.se HiQ is required by Swedish law (the Securities Market Act and/or the Financial Instruments Trading Act) to publish this information. This information was released for publication at 07:30 CET on 22 April 2015. For more information, please contact:Lars Stugemo, President and CEO, HiQ, Tel. +46 8 588 90 000Peter Häggström Lindecrantz, Head of Corporate Communications HiQ, Tel. +46 704 200 103HiQ helps to make the world a better place by making people’s lives simpler. We are the perfect partner for everyone eager to achieve results that make a difference in a digital world. Founded in 1995 HiQ currently has 1,400 specialists in four countries and is listed on the Nasdaq Stockholm MidCap list. For more information and inspiration, please visit www.hiq.se

Q1 2015 Interim report January−March

Q1 2015 Highlights · Net sales up 1% at constant FX & up 1% on an organic basis · Operating income before associated company income and non-recurring items of SEK 142m (118) including SEK 24m net positive effect of Swedish restructuring and copyright settlement in Scandinavia · Total EBIT of SEK 415m (301) including SEK 195m (183) of associated company income and SEK 77m (-) of non-recurring items · Net income of SEK 318m (159) and basic earnings per share of SEK 4.92 (2.43) · Cash flow from operations of SEK 201m (195), with net debt of SEK 396m (738) equivalent to 0.2x trailing 12 month EBITDA (excl. non-recurring items) Financial Overview +-------------------------------+-------+-------+-------+|(SEKm) | 2015| 2014| 2014|| |Jan-Mar|Jan-Mar|Jan-Dec|+-------------------------------+-------+-------+-------+|Net sales | 3,701| 3,597| 15,746|+-------------------------------+-------+-------+-------+|Growth at constant FX | 1%| 13%| 11%|+-------------------------------+-------+-------+-------+|Organic growth at constant FX | 1%| 5%| 4%|+-------------------------------+-------+-------+-------+|EBIT before associated company | 142| 118| 1,272||income and non-recurring items | | | |+-------------------------------+-------+-------+-------+|Margin before associated | 3.8%| 3.3%| 8.1%||company income and non | | | ||-recurring items | | | |+-------------------------------+-------+-------+-------+|Associated company income * | 195| 183| 558|+-------------------------------+-------+-------+-------+|EBIT before non-recurring items| 337| 301| 1,830|+-------------------------------+-------+-------+-------+|Non-recurring items (NRI) ** | 77| -| -155|+-------------------------------+-------+-------+-------+|Total EBIT | 415| 301| 1,675|+-------------------------------+-------+-------+-------+|Net Income | 318| 159| 1,172|+-------------------------------+-------+-------+-------+|Basic Earnings per Share (SEK) | 4.92| 2.43| 17.10|+-------------------------------+-------+-------+-------+|Net debt | 396| 738| 362|+-------------------------------+-------+-------+-------+|Cash flow from operations | 201| 195| 1,337|+-------------------------------+-------+-------+-------+ * Including MTG’s SEK 74m (USD 11.5m) Q1 2014 participation in USD 29.9m of non-recurring charges incurred by associated company CTC Media in Q4 2013. Including a net positive impact of SEK 18m in Q4 2014 relating to the closure of Raduga TV. ** Comprising in 2015 the SEK 77m capital gain from the sale of Swedish cable TV company Sappa. Comprising in 2014 the SEK 159m non-cash net impairment charge related to MTG’s interest in the Ukrainian satellite pay-TV platform; SEK 70m of organisational restructuring charges and other costs; and the SEK 76m capital gain from the sale of Zitius in Sweden. President & CEO’s comments Record Q1 sales & stable underlying profitsSales were up in the quarter to record levels as enhanced efficiency levels in our traditional businesses continued to fuel the growth of our digital businesses, and even though last year’s performance was boosted by the Olympics. Profits were stable compared to last year when excluding the net positive effect of the restructuring in Sweden and a copyright settlement in Scandinavia, and this is despite significant FX headwinds and continued investments in our digital products. The growth in online viewing is more than compensating for lower linear channel viewing levels in the Nordic region, and our combined Nordic TV businesses grew their sales, and profits were stable despite the FX impacts and when excluding the abovementioned net positive effect. Our Emerging Market free-TV operations generated higher sales and improved profitability in seven out of eight markets as we took shares in generally stable or growing markets. Our Emerging Market pay-TV operations continue to be impacted by the geopolitical crisis and Russia’s ban on advertising on most pay-TV channels. Nice, MTG Radio and MTGx reported stable sales and lower losses on a combined basis. Enhanced capital allocationWe continue to optimize our capital allocation and exited Sappa (Swedish cable-TV operator) and our FTV business in Hungary (subject to regulatory approval) in the quarter, in line with the previous exits from Zitius and Raduga. We are also taking ongoing action across the Group to focus and balance our costs and investments, in order to ensure that our products are as relevant and competitive as possible. At the same time, we are identifying and reviewing complementary and scalable digital investment opportunities, in order to concentrate our resources in areas that offer the greatest potential, which is why we have also recently increased our stake in Splay (biggest YouTube network in Sweden). Russia updateWe are exploring a range of options regarding our Russian operations and holdings, in order to comply with the changes to the Russian law regarding foreign ownership of Russian mass media companies from the beginning of 2016, and to seek to protect the stakeholder value that we have built up over a number of years. We have processes in place and will provide updates when we have significant further developments. OutlookWe have now almost finalized the annual upfront agreements for our free-TV businesses, with price increases in most markets reflecting TV’s unique reach and superior return on investment. Viaplay continues to grow its subscriber base and usage levels, while our channel packages are more broadly available than ever before. We have also added new programming content or extended valuable existing rights to ensure that we have the best possible entertainment offerings in each market. We continue to face adverse FX headwinds that are inflating our US dollar content costs in the Nordics particularly, and also reducing the results from our Russian ruble denominated operations. We are taking actions across the Group to offset these effects as much as possible. Jørgen Madsen LindemannPresident & Chief Executive Officer “Our strategic transformation continues and we have more customers enjoying our content and services than ever before. The underlying business continues to perform well but we are being impacted by significant FX headwinds.” Conference CallThe company will host a conference call today at 09.00 Stockholm local time, 08.00 London local time and 03.00 New York local time. To participate in the conference call, please dial: Sweden:                  +46 (0) 8 5033 6538 UK:                           +44 (0) 20 3427 1908 US:                           +1 646 254 3388 The access pin code for the call is 9769768. To listen to the conference call online and for further information, please visit www.mtg.com. Any questions?www.mtg.comFacebook: facebook.com/MTGABTwitter: @mtgabpress@mtg.com (or Per Lorentz +46 73 699 27 09)investors@mtg.com (or Stefan Lycke +46 73 699 27 14) Stockholm, 22 April 2015 Jørgen Madsen Lindemann, President & Chief Executive Officer Modern Times Group MTG ABSkeppsbron 18P.O. Box 2094SE-103 13 Stockholm, SwedenRegistration number: 556309-9158 MTG (Modern Times Group MTG AB (publ.)) is an international entertainment group. Our operations span six continents and include TV channels and platforms, online services, content production businesses and radio stations. We are also the largest shareholder in CTC Media, which is Russia’s leading independent media company. Our shares are listed on Nasdaq Stockholm (‘MTGA’ and ‘MTGB’). The information in this announcement is that which MTG is required to disclose according to the Securities Market Act and/or the Financial Instruments Trading Act, and was released at 07:30 CET on 22 April 2015.

INTERIM REPORT JANUARY – MARCH 2015

INCREASED PROFITS AND RECORD REVENUESJANUARY – MARCH 2015 · Net sales total SEK 391.3 (348.6) million · Operating profit (EBIT) of SEK 46.1 (36.1) million; operating margin of 11.8 per cent · Pre-tax profit of SEK 45.9 (36.1) million · Profit after tax of SEK 35.7 (27.8) million · Earnings per share of SEK 0.67 (0.53) · Cash flow from operations of SEK 26.1 (23.2) million · Liquid assets of SEK 204.3 (227.1) million SIGNIFICANT EVENTS DURING THE PERIOD · Annual General Meeting decides on a shareholders dividend of SEK 2.60 per share, totalling SEK 138.2 million, through a split and mandatory redemption programme · HiQ wins framework agreement with a global company within active safety in the automotive industry · HiQ develops new communication platforms for the city of Västerås, public transport in Västmanland county and Nordic Green Energy · Together with Tele2, HiQ wins the event award Gyllene Hjulet (“Golden wheel”) by simplifying for the people visiting Tele2 Arena · HiQ is acknowledged as one of Sweden’s Career Companies · HiQ contributes with technical know-how in the Ngulia project in Kenya, aiming to save the black rhino from extinction    · HiQ launches a new issue of the acknowledged HiQ Magazine  SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD · HiQ signs a framework agreement with Kammarkollegiet (The Legal, Financial and Administrative Services Agency) regarding system development · HiQ streamlines and implements processes for quality assurance and test for Finnish insurance company Fennia FOR FURTHER INFORMATION, PLEASE CONTACT:Lars Stugemo, CEO and President of HiQ, tel. +46 (0)8-588 90 000Peter H. Lindecrantz, Head of Corporate Communications, HiQ, tel. +46 (0)704-200 103This information is such as HiQ is required to make public according to the Swedish Securities Act and/or the Swedish Financial Instruments Trading Act. This report was released for publication at 07:30 CET on 22 April 2015.HiQ helps to make the world a better place by making people’s lives simpler. We are the perfect partner for everyone eager to achieve results that make a difference in a digital world. Founded in 1995, HiQ currently has 1,400 specialists in four countries and is listed on the NASDAQ Stockholm MidCap List. For more information and inspiration, please visit www.hiq.se

Aerocrine: Sales start of NIOX VERO® in Japan

SOLNA, Sweden – Aerocrine AB (NASDAQ Stockholm: AERO) The marketing and sales efforts of Aerocrine’s FeNO measuring device NIOX VERO® was launched Sunday the 19th at an event held at the Swedish Embassy in Tokyo in the presence of the Swedish Trade Commissioner Cecilia Leiram and attended by more than 50 leading Japanese pulmonologists. “The start of NIOX VERO® sales in Japan today follows the introduction of our new FeNO measuring device, NIOX VERO®, in the US and Europe. Current sales of our device NIOX MINO® that was launched in Japan in November 2013 has been above expectations and NIOX VERO® now joins NIOX MINO® as the only devices for FeNO measurements that are approved by PMDA for sale in  Japan.” stated Torben Thölix, International Sales Director at Aerocrine. “Aerocrine has had an excellent cooperation with Panasonic Healthcare in the joint development and manufacture of the NIOX VERO®. This is the first product based on this cooperation, now launched in Panasonic Healthcare’s home market and we are excited about getting direct feedback from the Japanese physicians attending this event” said Mats Carlson, VP at Aerocrine “We anticipate that the NIOX VERO® will be welcomed by the Japanese physicians and patients thanks to its portability and ease to use”, said Hideaki Hoki, president of Chest M.I Inc, exclusive distributor for NIOX products in Japan. “Aerocrine’s new portable device is an innovative Swedish designed product and a great example of what our unique Swedish medical system and its advanced approach to research and development can do to improve asthma patient’s daily life”, commented Cecilia Leiram, Swedish Trade Commissioner in Japan. According to the World Health Organization (www.who.int) fact sheet No 206 there are about 3 million asthmatics in Japan of whom 7% have severe and 30% have moderate asthma. Appendix: Photos from the launch event at the Swedish Embassy in Tokyo For more information, contact:Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +46 768 788 379, +1 970-368-0336Mats Carlson, VP Global Business Operations, Phone: +  About AerocrineAerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX VERO® and NIOX MINO® which enables fast and reliable point-of-care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the NASDAQ Stockholm since 2007. For more information please visit www.aerocrine.com and www.niox.com. 

Eltel’s annual report for 2014 published

Eltel has published the Annual Report for 2014 which is now available at Eltel’s website www.eltelgroup.com. The Annual Report can be ordered by e-mail to info@eltelnetworks.com. Eltel Business Segment names as from today are the following: Power, Communication, Transport & Security (former Transport & Defence). The Business Units under the Business Segments are named as follows: +--------------------+-----------------------------------------+|Segments |Business   Units |+--------------------+-----------------------------------------+|Power |Power Transmission, Power Distribution |+--------------------+-----------------------------------------+|Communication |Fixed Communication, Mobile Communication|+--------------------+-----------------------------------------+|Transport & Security|Rail & Road, Aviation & Security |+--------------------+-----------------------------------------+ The change does not imply any changes in organization, strategy, business plans or other plans for the company. For more information, please contact:Gunilla Wikman, Investor Relations Manager at Eltel ABtel: +46 725 843 630, gunilla.wikman@eltelnetworks.se Hannu Tynkkynen, Senior Vice President, Group Communications at Eltel ABtel: +358 40 3114503, hannu.tynkkynen@eltelnetworks.com About EltelEltel is a leading European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Transport & Security, with operations throughout the Nordic and Baltic regions, Poland, Germany, the United Kingdom and Africa. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a loyal and growing customer base of large network owners. The number of employees is approximately 8,600 and in 2014, Eltel net sales amounted to EUR 1,242 million. Eltel’s share is listed on Nasdaq Stockholm since February 2015.

NOTE’s Interim Report January–March 2015

Financial Performance January–March• Sales were SEK 275.3 (232.8) million.• Operating profit was SEK 11.9 (5.8) million.• Operating margin was 4.3% (2.5%).• Profit after financial items was SEK 11.0 (3.8) million.• Profit after tax was SEK 9.3 (3.1) million, corresponding to SEK 0.32 (0.11) per share.• Cash flow after investments was SEK 21.8 (23.1) million, or SEK 0.76 (0.80) per share. CEO’s comment"NOTE continued to advance on a fairly stable European market. In the first quarter, we achieved sales growth of over 18%, some one-half of the sales growth was attributable to currency exchange rate fluctuations. Sales increased in all domestics markets. It continues to look promising, order backlog at the end of the quarter supports a positive sales outlook.The combination of increased sales with continued good cost-efficiency contributed to our stronger profitability. Operating profit improved by SEK 6,1 million to SEK 11.9 million. Our operating margin expanded by 1,8 percentage points to 4.3%.Improved earnings, combined with stable progress of working capital, contributed to cash flow after investments of SEK 21.8 million, despite the sales growth. This was basically in line with the first quarter the previous year. NOTE’s balance sheet remains solid with an equity to assets ratio of 42,6%”, says Peter Laveson, President and CEO.NOTE’s Interim Report for January–March is now available in PDF format on the corporate web site, www.note.eu, and attached to this message. The Interim Report for January–June will be published on 13 July

Cerdo outsources its savings and payments services to Tieto

Tieto and Cerdo have signed a contract on outsourcing of administrative payments and savings services for the banking and financial sector. The agreement means that part of Cerdo´s personnel will be transferred to Tieto. This also means that Tieto can provide a sought-after outsourcing solution for the Nordic financial market. The combination of Cerdo's competences within Business Process Outsourcing (BPO) and developed business processes together with Tieto's IT and consultancy services enables Tieto to offer an integrated business solution in administrative payments and savings services to its customers. This strengthens Tieto's position as a leading partner for the banking and financial sector in the Nordic region. - We are pleased to be able to take on full responsibility for banks' administrative services, including system and process management. It enables our customers to focus on their core business and become more innovative and competitive, says Vahid Zohali, Vice President Banking at Tieto. Tieto and Cerdo have collaborated since 2006, mainly in the Fund, Securities and Card product areas. The companies have also together developed industry-specific cloud solutions for the banking and financial sector. - This is a natural step in a very fruitful collaboration. It is great that the customers now can be offered an even stronger service consisting of Tieto's expertise in IT together with Cerdo's solid business and process knowledge within the financial sector, says Anneli Ödén, Managing Director at Cerdo Bankpartner. For additional information, please contact Vahid Zohali, Vice President Banking, Tieto Swedenphone: +46 (0)73 725 22 00, e-mail: vahid.zohali[at]tieto.com Anneli Ödén, CEO, Cerdo Bankpartnerphone: +46 (0)70 598 49 03, e-mail: anneli.oden[at]cerdo.se About Tieto Tieto is the largest IT services company in the Nordics providing full lifecycle IT services. We also provide global product development services for companies in the communications and embedded technologies arena. Through industry insight, technology vision and innovative thinking, Tieto proactively strives to inspire and engage its customers in finding new ways of accelerating their business. Building on a strong Nordic heritage, Tieto combines global capabilities with local presence. Headquartered in Helsinki, Finland, Tieto has over 13 000 experts in more than 20 countries. Turnover is approximately €1.5 billion. Tieto’s shares are listed on NASDAQ in Helsinki and Stockholm. www.tieto.com About CerdoCerdo is a back office and administration company owned by Sparbanken Öresund, which is owned by Swedbank. Cerdo was founded in 2001 as an outsourcing company for Sparbanken Finn and Sparbanken Gripen. Over the years, Cerdo has converted a number of customers to its banking sector products and services. Cerdo's customers can therefore focus on their core business while back office and associated systems are outsourced to Cerdo. Cerdo's strength lies in managing and streamlining administrative processes and systems support, with extensive expertise and experience of companies in the banking and finance sector.

SKF opens hybrid production channel in Indonesia; secures contract with Honda

Gothenburg, 22 April 2015: SKF has opened a hybrid production channel in its manufacturing facility in Jakarta, Indonesia. This production channel has been designed to be able to produce two different types of product families: single-row deep groove ball bearings and double-row angular contact ball bearings, i.e. hub bearing units. As a result of its flexible production capabilities and local presence, SKF has also secured a contract for the supply of wheel hub bearing units for the Honda Jazz model. The agreement is valid until 2017 and deliveries will commence during the second half of 2015. Stephane Le-Mounier, President, Automotive Market says, “Developing manufacturing processes and systems that increase production utilization is key to improving our efficiency and, ultimately, our profitability. I am very pleased to see that this investment is providing value for both us and our customers. I am confident that we can offer customers increased benefits from our locally produced products, customer service and technical expertise.” Aktiebolaget SKF(publ) For further information, please contact:Media Hotline: +46 31 337 2400Press Relations: Theo Kjellberg, +46 31-337 6576; +46 725-776 576; theo.kjellberg@skf.comInvestor Relations: Marita Björk, +46 31-337 1994; +46 705-181 994; marita.bjork@skf.com SKF is a leading global supplier of bearings, seals, mechatronics, lubrication systems, and services which include technical support, maintenance and reliability services, engineering consulting and training. SKF is represented in more than 130 countries and has around 15,000 distributor locations worldwide. Annual sales in 2014 were SEK 70,975 million and the number of employees was 48,593. www.skf.com® SKF is a registered trademark of the SKF Group.

Financial Report January - March 2015

(Stockholm, April 22, 2015) – – – For the three-month period ended March 31, 2015, Autoliv, Inc. (NYSE: ALV and SSE: ALIV.Sdb) – the worldwide leader in automotive safety systems – reported consolidated sales of $2,174 million. Quarterly organic sales* grew by close to 4%. The adjusted operating margin* was 8.9% (for non-U.S. GAAP measures see enclosed reconciliation tables). The expectation at the beginning of the quarter was for organic sales growth of “around 3%” and an adjusted operating margin of “around 8%”. The higher than expected sales growth came mainly from strong sales in Europe. The reported operating margin of 3.7% was negatively affected by antitrust related settlements and the on-going capacity alignment in Europe by a total of around $113 million. For the second quarter of 2015, the Company expects organic sales to increase by around 6% and an adjusted operating margin of around 9%. The expectation for the full year is for organic sales growth of more than 6% and an adjusted operating margin of around 9.5%. Key FiguresFor Key Figures summary table, please refer to attached file below. Comments from Jan Carlson, Chairman, President & CEO“I am pleased with our first quarter performance. Organic sales and adjusted operating margin were both stronger than anticipated at the beginning of the quarter. These positive developments were primarily driven by strong sales in Europe, for both passive and active safety products, coupled with lower than anticipated overhead costs. For the quarter we again experienced strong growth in active safety and we continue to grow the business while investing in research and development for long term success in this growth area. As anticipated, our sales in China showed modest growth in the quarter. This was due to a challenging customer mix first experienced in the second half of 2014, which we expect will gradually improve throughout 2015. We have continued to adjust our capital structure and we have now reached a leverage ratio for the Company of 0.5 times, which is within our long-term target range of 0.5 to 1.5 times originally communicated at our Capital Market Day in 2013. This has primarily been achieved by direct shareholder returns through share repurchases and dividends. In our cyclical industry this range gives us flexibility to grow the Company while being prepared for potential costs associated with on-going antitrust matters. During the quarter we made progress in our antitrust related matters by reaching additional settlements and we continued to execute on our European capacity alignment program, which is important for the long term competitiveness of our European operations. We further executed well on our improvements in steering wheels and on our vertical integration strategy while our operations in Brazil remains a challenge due to the continued declining vehicle production. We continue into 2015 with strong focus on quality leadership, execution and further buildup of our active safety capabilities, while working towards our ultimate vision of saving more lives.” An earnings conference call will be held at 3:00 p.m. (CET) today, April 22. To follow the webcast or to obtain the pin code and phone number, please access www.autoliv.com. The conference slides will be available on our web site as soon as possible following the publication of this earnings report.

Interim report January-March 2015: Q1 in line with last year—strong growth in IDC

· Order intake was 343.5 MSEK (354.7). · Net sales increased by 2% to 351.8 MSEK (346.1). · A record quarter for IDC. · Operating profit up by 2% to 26.7 MSEK (26.2). · Profit after tax was 15.1 MSEK (15.1). · Earnings per share were 0.80 SEK (0.79). COMMENTS FROM ACTING CEO ANNA BELFRAGE “Beijer Electronics’ sales increased moderately and operating profit was up slightly in the first quarter. The IDC business area remains convincing. IDC’s sales increased by almost 30% and operating profit by just over 20%. Westermo had another record quarter in terms of sales, and the period was IDC’s strongest to date. The strategicinvestment program announced last fall is proceeding according to plan. The positive progress demonstrates the effectiveness of IDC’s far-ranging initiative, as well as its significant potential looking ahead. The IAS business area experienced a challenging quarter as a result of a downturn in US sales. Approximately half of the robust terminals sold in the US are intended for the oil and gas segment, and given the current low level of oil prices, investments in extraction have stagnated. To offset the lower volumes, we’ve initiated a range of activities, both to address the oil and gas distribution chain, and to increase sales to other segments that require rugged terminals, such as mining. Demand remained sluggish in the Nordics, which also affected IAS’ sales negatively. Progress in the rest of Europe and Asia was more positive, however, with increased sales, particularly for the global product offering. The measures in IAS that were begun towards the end of last year are proceeding according to plan, and generated currency-adjusted savings of 8 MSEK in the quarter. Given IAS’ current situation, work is underway to identify further savings measures. Developments in the US have affected group profitability, but the goal of improving underlying operating profit stands.” INVITATION TO CONFERENCE CALL Today, April 22, 2015, a conference call will be held for press and analysts where acting President and CEO Anna Belfrage and acting CFO Joakim Nideborn present the company and comment on the report. Time:  Wednesday April 22, at 2.00 p.m. CET To participate in the conference please dial: From Sweden: +46856642669From UK: +442034281400 To access the presentation please use this link:https://www.anywhereconference.com/?Conference=103362817&PIN=987020 The report and the presentation will be available at Beijer Electronics’ website www.beijergroup.com under Investors/Presentations. A recording of the conference call will also be available here after the event. Welcome!

Writer-Director Kim Bass Acquires Film Rights to JEWBOY vs THE LUFTWAFFE

Los Angeles, CA – April 22, 2015 – Bass Entertainment has acquired the rights to unpublished autobiographical book “JEWBOY vs THE LUFTWAFFE” written by multi-decorated WWII fighter pilot and American hero, Philip M. Goldstein. Award-winning and Emmy-nominated writer-director Kim Bass  (http://www.imdb.com/name/nm0060076/?ref_=tt_ov_wr)will pen and direct the bio-pic of the now 94 year-old Army Air Corps veteran and Lockheed P-38 Lightning fighter ace. In 1941, after learning about the atrocities being committed by the Nazis, 21 year-old Goldstein requested a discharge from the U.S. Army and its Regimental Band and enlisted in the U.S. Army Air Corps. Despite the anti-Semitism of many of his superiors and squadron mates, he flew 50 harrowing, death-filled missions against Hitler’s mighty and merciless Luftwaffe.  Goldstein shot down his first Nazi adversary on his very first mission after which his Crew Chief painted “JEWBOY” on his plane “so the Luftwaffe pilots would know who was blowing them out of the sky.” Goldstein would go on to rack up more kills than he is comfortable talking about.  For his extraordinary heroic feats of aerial combat – which included saving the life of a fellow flier over German-controlled airspace hundreds of miles behind enemy lines – he was awarded a Distinguished Flying Cross, an Air Medal with clusters as well as a Presidential Citation.  Of the forty four P-38 Lightning pilots who shipped out across the Atlantic Ocean on his troop transport, only 2ndLt. Philip M. Goldstein would survive to tell their heroic tale. “Our job was to clear the skies of Hitler’s air force so our boys wouldn’t get cut to pieces on the ground from the air.  We were just kids, but we did our job,” says Goldstein. “Mr. Goldstein’s story, like so many untold stories of so many unsung heroes, is one of overcoming incredible odds and displaying unimaginable bravery and selfless brotherhood, in the midst of that most brutal of human endeavors—war.  Once I read his book and had the privilege to meet him in person and listen to what he had to say about what he had witnessed and how he had carried out orders and done his duty (much of it under undeserved duress) at 20,000 feet and at over 400 miles per hour, alone in a tiny, plastic-canopy-covered cockpit, strapped in a seat atop four 50 caliber machine guns and a 20mm canon, I was hooked and had to tell his unbelievable story.  I am both honored and humbled to have been entrusted with such amazing material by an amazing American.” said Bass, who is himself a commercial-rated jet pilot.  Bass, who recently wrapped principal photography on his latest film, the inspirational, two-character drama, Day of Days (http://www.imdb.com/title/tt3779382/?ref_=nm_flmg_wr_3), starring award-winning, “Top Gun (http://www.imdb.com/title/tt0092099/?ref_=nm_knf_i2)” star, Tom Skerritt  (http://www.imdb.com/name/nm0000643/?ref_=tt_cl_t1)and Peruvian newcomer, Claudia Zevallos (http://www.imdb.com/name/nm2347043/?ref_=tt_cl_t2), intends to set up JEWBOY vs THE LUFTWAFFE for production in 2016. For more information visit:  www.jewboyvstheluftwaffethemovie.com

Steam power will mark start of 'Cote de Grosmont' in the Tour de Yorkshire

Who needs a starting pistol when you have the joint power of three steam engines?  Three locomotives will send huge plumes of steam into the air to mark the start of the ‘Cote de Grosmont’ section of the Tour de Yorkshire on Friday 1 May 2015, which will depart from the level crossing between the three engines! The Cote de Grosmont stage is just one of the times the epic cycling race will come close to the railway as it travels through Pickering and Whitby during Stage 1, although this is the only time that it actually crosses the rails – and organisers from the North Yorkshire Moors Railway are making sure that it gets the best possible send-off for the 400m climb up through the village of Grosmont. “The North York Moors National Park is probably the most stunning part of the route of the Tour de Yorkshire, and with the North Yorkshire Moors Railway an arterial route through the countryside, we had to mark this stage in impressive style,” comments Danielle Ramsey, marketing manager for NYMR.  “We are laying on extra services, and working with Northern Rail to extend our services to make it easier for those travelling down from Middlesbrough to get to the heart of the races, and of course, having three engines on one side of the crossing will create an absolutely iconic image during this stage – fantastic for cycle enthusiasts, photographers and anyone looking for a wonderful day out during this inaugural race!” Indeed, with rolling road closures throughout the county during the Tour de Yorkshire, the heritage railway and Northern Rail services are likely to be one of the most reliable ways of getting around the region throughout the Tour weekend and, indeed, an extra marquee will be installed on Platform 2 at Grosmont Station to extend the tea room for visitors, serving delicious local produce and will be fully licenced for celebratory tipples! “Sadly, neither we nor Northern Rail have the capacity to transport more than a couple of bikes into the region, and we advise against ‘race chasers’ trying to get from one point on the stage to another, but we will be making the most of the party atmosphere all weekend, and giving visitors a great reason to enjoy the railway’s charms!” adds Danielle. Carolyn Watson, head of communications for Northern Rail said, “With the party atmosphere returning to Yorkshire we’re looking forward to taking spectators to the Tour.  Through our partnership with NYMR we’re making it as easy as we can for customers travelling by train.  Extra services and longer trains mean more opportunities to travel and tickets issued by both companies will be valid on any train between Battersby and Whitby.” Opportunities for those visiting the North Yorkshire Moors Railway to see the Tour de Yorkshire on Friday 1 May are: · Approximately 1.45pm in Pickering town centre (10am service from Whitby arrives at 11.55am to get the best view) · Approximately 3.00pm at Grosmont (12.30pm service from Pickering, 12.50pm service from Whitby or 10.57am Northern service from Battersby) · Approximately 3.18pm in Whitby (12.30pm service from Pickering, or 10.57am Northern service from Battersby) For more information about the special North Yorkshire Moors Railway timetable running for the Tour de Yorkshire, please visit www.nymr.co.uk.  For more information about Northern Rail services please visit northernrail.org/tourdeyorkshire ENDS For further media information or photographs, please contact: Jay Commins Pyper York Limited Tel:         01904 500698 Email:    jay@pyperyork.co.uk

Interim report January–March 2015

· Incoming orders amounted to SEK 780.7m (620.3), which adjusted is an increase of 10.8%*). · Net sales amounted to SEK 727.2m (623.2), which adjusted is an increase of 1.8%*). · The operating profit excluding acquisition and restructuring costs was SEK 38.1m (18.6). The adjusted operating margin was 5.2% (3.0). · The operating profit was SEK 38.1m (8.6). The operating margin was 5.2% (1.4) · The net profit was SEK 23.9m (1.5). · Earnings per share were SEK 2.04 (0.13). *) adjusted for currency effects and acquisitions CEO’s comments“The development of orders received by the Group was good during Q1. The Americas region especially saw strong progress during the quarter, and orders in the EMEA region also saw a positive trend. In the APAC region the picture was more mixed at the start of 2015, with orders staying at the same level as in Q1 2014. The Group’s profitability strengthened during the quarter. The operating profit, excluding restructuring and acquisition costs, doubled compared with the same period in 2014. The positive development in earnings capability is primarily related to higher volumes and lower underlying costs, as well as the weaker Swedish krona, which affected earnings positively. Sven Kristensson, CEO   Nederman is required to disclose the information provided herein according to the Swedish Securities Exchange and Clearing Operations Act and/or the Financial Instrument Trading Act. The information was submitted for publication on 22 April 2015 at 4 p.m. Further information can be obtained fromSven Kristensson, CEOTelephone +46 (0)42-18 87 00        email: sven.kristensson@nederman.com  (sven.kristensson@nederman.com)Stefan Fristedt, CFOTelephone +46 (0)42-18 87 00email: stefan.fristedt@nederman.com For further information, see Nederman’s website www.nederman.com Nederman Holding AB (publ),Box 602, SE-251 06 Helsingborg, SwedenTelephone +46 (0)42-18 87 00, Telefax +46 (0)42-18 77 11Co. Reg. No. 556576-4205 Facts about Nederman Nederman is one of the world's leading companies supplying products and systems in the environmental technology sector focusing on industrial air filtration and recycling. The company's solutions are contributing to reducing the environmental effects from industrial production, to creating safe and clean working environments and to boosting production efficiency.   Nederman's offering encompasses everything from the design stage through to installation, commissioning and servicing. Sales are carried out via subsidiaries in 25 countries and agents and distributors in over 30 countries. Nederman develops and produces in its own manufacturing and assembly units in Europe, North America and Asia. The Group is listed on the Nasdaq OMX, Stockholm Mid Cap list; it has about 1,900 employees and a turnover of about SEK 2.8 billion.

Montgomery College President Dr. DeRionne P. Pollard Named 2015 Emerging Leader by American Association of Community Colleges

-- Award Recognizes CEOs Who Have Developed Exemplary Systems of Leadership and Professional Development.  Montgomery College President Dr. DeRionne P. Pollard has been honored with the Emerging Leader Award by the American Association of Community Colleges (AACC). Pollard was recognized for the development of a new mission, a bold strategic plan, the creation of innovative partnerships, and a new academic structure. The award was presented on April 20 as part of the 95th AACC convention program in San Antonio.“I am honored and humbled to have received this award from AACC. This recognition is truly for the many dedicated faculty and staff at Montgomery College who work very hard every day to make a difference in students’ lives,” Pollard said.Attention Editors: For a high-resolution image to accompany this release, click here.Since her 2010 inauguration as president of Montgomery College, Dr. Pollard has spearheaded a new mission and Montgomery College 2020, the institution’s strategic plan. Other priorities have included developing partnerships with community organizations and internationally recognized corporations. These include Holy Cross Health, which opened a new hospital at the Hercules Pinkney Life Sciences Park on the College’s Germantown Campus this past year; partnering with Montgomery County Public Schools and the Universities at Shady Grove in the creation of Achieving Collegiate Excellence and Success (ACES), a support program designed to help students transition from high school to college completion.Dr. Pollard is a proud graduate of Leadership Montgomery, and was named its Outstanding Leader for 2013. Other awards and honors include Washingtonian Magazine’s 100 Most Powerful Women; the Daily Record’s Influential Marylander; and Washington Business Journal’s Minority Business Leader Award. Dr. Pollard formerly served as president of Las Positas College in Livermore, California. Her community college career began at College of Lake County (Ill.) as a faculty member in English. She received her PhD in educational leadership and policy studies in higher education from Loyola University Chicago and her MA and BA in English from Iowa State University.Winners of the AACC awards were selected by a committee of the AACC Board of Directors. The AACC  represents and advocates for nearly 1,200 associate-degree granting institutions enrolling more than 13 million students—almost half of all U.S. undergraduates.###Montgomery College is a public, open admissions community college with campuses in Germantown, Rockville, and Takoma Park/Silver Spring, plus workforce development/continuing education centers and off-site programs throughout Montgomery County, Md. The College serves nearly 60,000 students a year, through both credit and noncredit programs, in more than 130 areas of study.

Huntington’s Disease Society of America Announces Winners of 2015 Donald A. King Summer Research Fellowship

Scientists working at Gladstone Institute for Neurological Disease, University of Pittsburgh and Boston University Medical School awarded fellowships to work on Huntington’s disease projects New York, NY (April 21, 2015) — The Huntington’s Disease Society of America (HDSA) is pleased to announce the recipients of the 2015 Donald A. King Summer Research Fellowships, a vital program to train the next-generation of scientists with research expertise in neurodegenerative disorders, especially Huntington’s disease. This year, a record number of applications from across the country were received. The HDSA Scientific Advisory Board carefully reviewed and scored the proposals using several criteria such as: the quality of the candidate’s academic achievements, mentoring plan for candidate, scientific rigor of the experimental design and feasibility to achieve significant deliverables in a short summer timeframe. Three impressive students were selected as recipients of the 2015 Donald A. King Summer Research Fellowship: · Valentina Lagomarsino (Boston University) will be working at Boston University Medical School under the guidance of Dr. Richard Myers on a project entitled “Cerebrospinal fluid based miRNA biomarkers for Huntington’s disease progression”. miRNAs (or microRNA) are non-coding RNAs that act to regulate gene expression. Valentina’s project aims to confirm the presence of five miRNAs in human cerebrospinal fluid and determine if the levels of these miRNAs correspond to the clinical stage of HD. · Rogan Grant (Haverford College). Rogan will spend the summer working with Dr. Joseph Glorioso on a project entitled “Development of an inducible CRISPR/Cas9 vector for huntingtin knockout”. Rogan’s project involves development of a promising genome-engineering tool called the CRISPR/Cas9 system to lower huntingtin. This huntingtin lowering tool will be expressed in human HD neurons using viruses that have the potential to cross the blood-brain-barrier. Use of brain penetrating viruses could increase the chances of delivering huntingtin lowering drugs to deep regions of the brain. · Brianna Bibel (St. Mary’s College of California). Brianna will be working under the guidance of Dr. Steven Finkbeiner from the Gladstone Institute for Neurological Disease, as well as Dr. Vanessa Wheeler from Massachusetts General Hospital on a project entitled “Elucidating the role of somatic expansion in human HD neurons degeneration with nanobiopsy and longitudinal single cell analysis”. Brianna will combine the use of Dr. Finkbeiner’s automated microscopy technology and nanobiopsy of human HD neurons to determine if the number of CAG repeats in individual HD neurons expands over time and whether this expansion happens before neurodegeneration occurs.   HDSA established the Donald A. King Summer Research Fellowship program in 2005 in honor of Donald King who passed away in 2004. Don was a tireless advocate for HD families and served as HDSA’s Chairman of the Board from 1999 to 2003. The purpose of this fellowship program is two-fold: first, to attract the brightest young scientists into the field of Huntington’s disease research and secondly, to facilitate meaningful HD research to clarify the biological mechanisms underlying HD pathology. Congratulations Valentina, Rogan and Brianna! We look forward to hearing about their promising research at upcoming HDSA meetings.   ###   Huntington’s disease is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. It deteriorates a person’s physical and mental abilities during their prime working years and has no cure. HD is known as the quintessential family disease because every child of a parent with HD has a 50/50 chance of carrying the faulty gene. Today, there are approximately 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.   The Huntington’s Disease Society of America is the premier nonprofit organization dedicated to improving the lives of everyone affected by HD. From community services and education to advocacy and research, HDSA is the world’s leader in providing help for today and hope for tomorrow for people with HD and their families.   To learn more about Huntington’s disease and the work of the Huntington’s Disease Society of America, visit www.hdsa.org or call (800)345-HDSA.  

Intrum Justitia’s Annual General Meeting 2015

BoardThe Annual General Meeting re-elected Lars Lundquist, Matts Ekman, Charlotte Strömberg, Synnöve Trygg, Fredrik Trägårdh, and Magnus Yngen as Board Members. Ragnhild Wiborg was elected as new board member.The Annual General Meeting re-elected Lars Lundquist as Chairman of the Board. AuditorsThe annual general meeting elected E&Y AB as auditor for the period until the end of the next annual general meeting. The auditing firm has appointed the authorised public accountant Erik Åström as auditor in charge. DividendThe annual general meeting adopted the board’s proposal for a dividend of SEK 7.00 per share (5.75). The record day for the dividend is Friday, 24 April 2015. The dividend is expected to be distributed by Euroclear on Wednesday, 29 April 2015. Buyback and transfer of own sharesIn accordance with the board’s proposal, the meeting authorised the board to until the end of the next annual general meeting resolve on purchase and transfer of the Company’s own shares on NASDAQ OMX Stockholm. The aggregated holding of the Company’s own shares shall not at any time exceed 10 per cent of the total number of shares in the Company. Guidelines for remuneration and other terms of employment for key executivesThe annual general meeting approved the board’s proposed guidelines for remuneration and other terms of employment for key executives. The total remuneration is based upon four main components; base salary, short- and long term variable salary programs and pension. Remuneration to the boardThe remuneration to the board and for committee work was established to a total of SEK 3.605.000 to be distributed as follows: · SEK 865.000 to the chairman of the board · SEK 360.000 to each of the other board members · SEK 170.000 to the chairman of the audit committee · SEK 85.000 to each of the other two audit committee members · SEK 80.000 to each of the three members of the remuneration committee Cancelation of repurchased sharesIn accordance with the board’s proposal, the meeting resolved to cancel the company’s repurchased shares. Minutes of meetingMinutes of the annual general meeting will be available in Swedish on the Company’s webpage within approximately two weeks. For further information, please contact:Lars Wollung, CEO and President, tel: +46 8 546 102 02Erik Forsberg, CFO, tel: +46 8 546 102 02

NORDIC NANOVECTOR – SHARE CAPITAL INCREASE IN CONNECTION WITH OVER-ALLOTMENT OF SHARES

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT.NORDIC NANOVECTOR – SHARE CAPITAL INCREASE IN CONNECTION WITH OVER-ALLOTMENT OF SHARES Oslo, 23 April 2015. Reference is made to the stock exchange announcement published 22 April 2015 regarding end of stabilisation and exercise of the over-allotment option in respect of the shares in Nordic Nanovector ASA (“Nordic Nanovector”, the “Company”, OSE ticker code: “NANO”) in connection with Nordic Nanovector’s initial public offering (the “Offering”). The Company’s board of directors has resolved, pursuant to an authorisation granted by the annual general meeting held on 9 March 2015, to increase the share capital of the Company by issuance of 2,343,750 new shares to ABG Sundal Collier Norge ASA at a price per share equal to the offer price in the Offering (i.e. NOK 32) under the over-allotment option granted to ABG Sundal Collier Norge ASA (on behalf of the managers for the Offering).  Following the issuance of the new shares, the share capital of Nordic Nanovector will be NOK 8,903,808.20 divided into 44,519,041 shares with a nominal value of NOK 0.20 each and Nordic Nanovector will receive NOK 75 million in additional proceeds from the Offering and accordingly, total gross proceeds from the Offering increases to NOK 575 million. For further queries, please contact:Luigi Costa, CEOCell:    (41) 79 124 8601Fax:    (47) 22 58 00 07E-mail: lcosta@nordicnanovector.com Tone Kvåle, CFOCell:    (47) 91 51 95 76Fax:    (47) 22 58 00 07E-mail: tkvale@nordicnanovector.com About Nordic NanovectorNordic Nanovector is a biotech company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radio-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of Non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin™ comprises a tumor-seeking anti-CD37 antibody conjugated to low intensity radionuclide (Lutetium 177). It has shown promising efficacy in Phase 1 studies in a difficult-to-treat NHL patient population and as well as a very favourable tolerability. Betalutin™ is fast advancing through clinical development and with first approval anticipated in 2018.Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialization of Betalutin™ in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat a number of select cancer indications. Further information about the Company can be found at www.nordicnanovector.com. IMPORTANT INFORMATIONUnited StatesThese materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the “Shares”) of Nordic Nanovector ASA (the “Company”) in the United States, Norway or any other jurisdiction. The Shares of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”). The Shares of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to “qualified institutional buyers” as defined in Rule 144A under the U.S. Securities Act. European Economic AreaAny offering of securities will be made by means of a prospectus to be published that may be obtained from the issuer or selling security holder, once published, and that will contain detailed information about the Company and its management, as well as financial statements.These materials are an advertisement and not a prospectus for the purposes of Directive 2003/71/EC, as amended (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not subscribe for any securities referred to in these materials except on the basis of information contained in the prospectus.In any EEA Member State other than Norway (from the time the prospectus has been approved by the Financial Supervisory Authority of Norway, in its capacity as the competent authority in Norway, and published in accordance with the Prospectus Directive as implemented in Norway) that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at “qualified investors” in that Member State within the meaning of Article 2(1)(e) of the Prospectus Directive (“Qualified Investors”), i.e., only to investors to whom an offer of securities may be made without the requirement for the Company to publish a prospectus pursuant to Article 3 of the Prospectus Directive in such EEA Member State. United KingdomIn the United Kingdom, these materials are only being distributed to and are only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as “Relevant Persons”). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Interim report January-March 2015

First quarter January-March 2015 · Order intake was SEK 471 (287) million · Order backlog was SEK 869 (193) million · Net sales were SEK 304 (242) million · EBIT was SEK 26 (3) million · Earnings per share were SEK 0.19 (0.01) OutlookThe Board’s assessment is that sales in 2015 will be in the span SEK 1,650-1,750 million. Stable start to the year “This year opened well for Mycronic, even without any mask writer deliveries during the first quarter. Demand for our products has been favorable and we are leaving the quarter with a record high order backlog,” says Lena Olving, CEO and president of Mycronic AB.The electronics industry continues to grow. In 2014 the industry grew 3.5 percent. Growth is expected to continue at this pace for several more years.The semiconductor industry also grew in 2014, which created a rising need for SMT equipment. The global market for SMT equipment has recovered after the negative trend of the last couple years and grew by 22 percent in 2014.Mycronic's launches of production solutions for effective electronics production has led to increases in the order intake and sales, and has strengthened Mycronic's market position. At the end of February, Mycronic launched the latest improvements in functionality within SMT.During the first quarter, Mycronic received orders for three mask writers within PG, one of which was the first based on the replacement strategy for older mask writers for the manufacture of displays. Demand for photomasks remains healthy, which leads to stabilization of prices and manufacturers' profitability is either maintained or improved. This, together with the high degree of utili-zation on Mycronic's mask writers installed at customer sites, indicates possibilities for further investments in capacity as well as for new, more advanced equipment. “Sales in our partially cyclical business are usually some-what lower during the first quarter than during the rest of the year. Sales have been positively affected by ex-change rates in the amount of SEK 49 million, especially the US dollar. The EBIT margin of 8 percent is also partly explained by the currency effects. But we have also done a lot to increase internal efficiency throughout the Group. We continue to invest in development of new products for customers' changing needs, and in strengthening the sales organization for growth in, for example, Asia. Thanks to our strong product offering, we can deliver strong results and simultaneously invest in the future,” Lena Olving concludes. Contacts at Mycronic:Lena OlvingCEO and President+46 8 - 638 52 00lena.olving@mycronic.com                                          Per EkstedtCFO+46 8 - 638 52 00per.ekstedt@mycronic.com About MycronicMycronic AB is a high-tech Swedish company engaged in the development, manufacturing and marketing of production equipment to the electronics industry. Mycronic headquarters is located in Täby, north of Stockholm and the Group has subsidiaries in China, France, Germany, Japan, Singapore, South Korea, Taiwan, the Netherlands, United Kingdom and the US. For more information, see our web site at www.mycronic.com.Mycronic AB (publ) is listed on NASDAQ Stockholm, Mid Cap: MYCR.

Clavister Appoints Stephan Schmidt to EMEA Channel Manager

Schmidt has over 20 years’ experience in senior IT sales and business development roles where of 6 years in IT Security, having previously worked for Dell, Nordic Edge, Intel Security and McAfee before joining Clavister in August of last year. “Stephan’s knowledge of the security sector and channel, together with his sales management skills, will add real strength to our European team” said Jim Carlsson of Clavister.  “His background and experience will help ensure that we continue to strengthen new and existing relationships, and maximize business opportunities.” In recent months Clavister has experienced an increased interest for its solutions in the EMEA region and with the release of new next generation security gateways including the entry level W30 and the E80, a security gateway that delivers enterprise-class capacity, featuring a desktop form-factor, bringing unmatched price/performance capability to SME and branch office deployments “This is an exciting time to be working at Clavister as the company expands and moves into new markets. I am looking forward to the challenge of helping our existing channel partners grow their businesses while also increasing our global network of value added resellers,” commented Schmidt. Schmidt will be responsible for developing Clavister’s channel strategy which has already seen success this year. The company has recently announced deployment with CNB (Coöperatieve Nederlandse Bloembollencentrale), the world’s largest authority in plant bulbs, through Dutch distributor BlackIP and an extension of its agreement with Croatian partner itSoft seeing the ISP offer Clavisters SECaaS offering to its entire customer base. 

Intrum Justitia repurchases own shares

On 22nd April 2015, the Board of Directors of Intrum Justitia AB (publ) resolved to initiate a share repurchase program. The purpose of the program is to reduce Intrum Justitia’s share capital by canceling the shares that are repurchased. Through the program, Intrum Justitia will return further funds to shareholders and it is the assessment of the Board of Directors that this will give the company a more optimal capital structure. Intrum Justitia’s Annual General Meeting of 22nd April 2015 authorized the Board of Directors to make decisions regarding the repurchasing of shares. The Board of Directors is now exercising this authorization and intends to conduct share repurchases during the period 23rd April to 16th June 2015. The program is being carried out in accordance with the European Commission’s ordinance (EC) No 2273/2003 of 22nd December 2003 (the EC ordinance) and will be managed by a securities company or credit institution that makes its trading decisions regarding Intrum Justitia’s shares independently and uninfluenced by Intrum Justitia. Any additional repurchases through block transactions will not be made in accordance with the exemption in the EC ordinance and will be managed by a securities company or credit institution in consultation with Intrum Justitia. The repurchases of the company’s own shares will meet the following terms: 1. Repurchases of shares are to be made on the Nasdaq Stockholm Exchange and in accordance with Nasdaq Stockholm’s regulations for issuers and in accordance with the EC ordinance. 2. Repurchases of shares on the Nasdaq Stockholm Exchange are to be made at a per-share price within the registered interval for the going rate at any given time, which denotes the interval between the highest and lowest selling price. 3. A maximum of 7,342,132 shares may be repurchased, corresponding to 10 percent of shares in the company. 4. Shares for a maximum SEK100 M may be repurchased. 5. Payment for the shares is to be made in cash. Intrum Justitia currently holds 3,939,616 own shares. The Annual General Meeting of 22nd April 2015 resolved to reduce the share capital in the company by canceling these shares. The Board of Directors intends to propose to the 2016 Annual General Meeting that the share capital in the company be reduced by canceling the shares that will now be repurchased. For further information, please contact: Erik Forsberg, Chief Financial OfficerTel: +46 (0)8 546 102 02E-mail: erik.forsberg@intrum.com

Interim report January-March 2015

Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2014. First quarter shows continued sales growth and positive cash flow. Broadening of Zubsolv® dosage range proceeds. First quarter 2015 · Total net revenues amounted to MSEK 149.0 (101.9). · Earnings after tax were MSEK -15.5 (-21.1). · Earnings per share were SEK -0.45 (-0.66). · Cash flow from operating activities was positive and amounted to MSEK 6.5 (-99.7). · Cash and cash equivalents amounted to MSEK 289.3 (30.7). · Orexo broadened Zubsolv product range by launching Zubsolv 8.6 mg. · FDA accepted submission of 2.9 mg Zubsolv dosage. · Orexo announced newly listed granted US patent. · Orexo commenced patent infringement litigation against Actavis concerning Abstral in the US. After the period · David Colpman was elected as a new board member at the AGM on April 15, 2015. · New clinical data establish Zubsolv as effective, well tolerated for maintenance treatment of opioid dependence and increases patients’ work productivity. +-----------------------------------+-------+-------+-------+|MSEK | 2015| 2014| 2014|+-----------------------------------+-------+-------+-------+| |Jan-Mar|Jan-Mar|Jan-Dec|+-----------------------------------+-------+-------+-------+|Net revenues | 149.0| 101.9| 570.3|+-----------------------------------+-------+-------+-------+|Revenues from launched products | 149.0| 101.9| 568.6|+-----------------------------------+-------+-------+-------+|EBIT | -8.1| -16.2| -25.0|+-----------------------------------+-------+-------+-------+|EBITDA | -5.1| -13.7| -12.5|+-----------------------------------+-------+-------+-------+|Earnings after tax | -15.5| -21.1| -56.6|+-----------------------------------+-------+-------+-------+|Earnings per share, SEK | -0.45| -0.66| -1.73|+-----------------------------------+-------+-------+-------+|Cash flow from operating activities| 6.5| -99.7| -487.3|+-----------------------------------+-------+-------+-------+|Cash and cash equivalents | 289.3| 30.7| 284.5|+-----------------------------------+-------+-------+-------+ TeleconferenceCEO Nikolaj Sørensen and CFO Henrik Juuel will present the report at a teleconference on April 23, 2015 at 2:00 pm CET (08:00 am EDT). Presentation slides are available via the link and on the website.Internet: http://financialhearings.nu/150423/orexo/Telephone: +46 8 566 426 65 (SE), +44 20 342 814 02 (UK), +1 855 753 22 35 (US) For further information, please contact:Nikolaj Sørensen, CEO or Henrik Juuel, EVP and CFOTel: +46 (0)18 780 88 00, E-mail: ir@orexo.com   CEO’s commentsIn the first quarter we experienced continuing growth in demand of Zubsolv® and a 0.4 percentage point improvement in market share from 5.73 percent to 6.13 percent , based on the four-week rolling market share in daily dosages. Looking deeper into market dynamics we have seen some significant changes in market share. In particular with WellCare, where start-of-the-year movements between insurance programs have led to a declining in overall market share of 0.3 percentage point. This loss of market share has been more than compensated by increased market share at United Health Group, an exclusive contract with Independent Health Associates (Buffalo, NY) and a gain in market share with the two largest PBM”s, ESI and CVS Caremark.We have reached positive cash flow during the first quarter, further strengthening our financial position. However our future cash flow generation is highly dependent on our decision to invest in further development and commercialization of Zubsolv. We will initiate a new clinical study and continue the controlled expansion of the field force during 2015 to drive additional sales and market share capture in the US.  In March, we launched our first new higher strength Zubsolv tablet (8.6 mg/2.1 mg buprenorphine/naloxone). This is the first of several new dosages of Zubsolv that we plan to launch this year. Also during the first quarter the FDA accepted our submission of a 2.9 mg/0.8 mg buprenorphine/naloxone dosage. We anticipate approval of this new dosage during the third quarter and a coordinated launch in combination with the previously approved 11.4 mg/2.9 mg buprenorphine/naloxone dosage. We also completed our clinical cohort study OX219-008, which together with the previous ISTART study confirms that the safety, tolerability and efficacy are comparable to our largest competitor and that there is a strong patient preference for Zubsolv.A key focus for Orexo is to continue broadening the prescriber base. We have seen market share among our 4,800 consistent prescribers increase to more than 11 percent at the end of the quarter. In all of the exclusive contracts we have won, we have seen the prescribers involved starting to prescribe to other patients, for example in the WellCare districts the prescription of Zubsolv to patients without WellCare insurance doubled following the exclusive contract with WellCare starting November 1, 2014. Currently, to further broaden the Zubsolv prescriber base, we are selectively increasing our field force where we gain reimbursement from additional payers, enabling a broader reach to more prescribers. We continue to pursue improvements in market access and expect to see additional agreements during the second half of 2015.The work of finding partner for Zubsolv outside the US and a partner for the final development and commercialization of OX51 has been initiated. We have received expressions of interest in both of these products, from both regional and global pharmaceutical companies. We anticipate that we will have selected a partner late this year for at least one of these products.My colleagues at Orexo and I remain dedicated to ensuring that Zubsolv continues to gain market share and becomes available to more patients as the drug of choice, thus helping them in their fight against opioid addiction.Nikolaj SørensenPresident and CEO[1] Wolter Kluwer/www.redeye.se   Please noteOrexo AB publ discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Market Act. The information was provided for public release on April 23, 2015, at 8:00 a.m. This report has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall prevail.

THE NOMINATION COMMITTEE’S PROPOSALS TO THE ANNUAL GENERAL MEETING IN KARO BIO AB (PUBL)

Prior to the annual general meeting 2015, the Nomination Committee has consisted of Anders Lönner (chairman), chairman of the board, representing own holdings, Göran Wessman, representing own holdings (Protem Wessman AB), Johan Paulsson, representing own holdings (JPMP i Visby AB), Leif Edlund, representing Johan Edlund and Per-Anders Johansson, representing own holdings (Nomic AB). Anders Lönner has been elected chairman of the Nomination Committee. The nomination committee proposes re-election of the board members Anders Lönner, Thomas Hedner, Göran Wessman, Per-Anders Johansson and new election of Jean Lycke. Sibylle Lenz and Christer Fåhraeus have declined re-election. Anders Lönner is proposed to be elected chairman of the board. Jean Lycke (born 1964), has great experience of business development within the pharmaceutical industry. Jean Lycke is, among other things, chairman of the board of Tanomed AB, board member and managing director of Emerentia Gruppen AB, board member of BioResonator Good Eye AB and Santax Nordic A/S. Jean Lycke holds presently no shares in the company. The Nomination Committee is of the opinion that the remuneration to the board should remain unchanged and be paid by SEK 420,000 to the chairman and SEK 150,000 to each of the other directors. The Nomination Committee further proposes re-election of the accounting firm PricewaterhouseCoopers AB and that remuneration to the auditor be paid as per approved invoice. Advokat Madeleine Rydberger is proposed to be chairman of the meeting. The Nomination Committee’s reasoned statement on its proposals to the annual general meeting will be published on the company’s website as soon as it is received by the company. For further information, please contact:Henrik Palm, CFO, email henrik.palm@karobio.se, telephone +46 70 540 4014 About Karo BioKaro Bio is a development company focused on broadening its operations to include projects and products closer to market. Karo Bio has several projects approaching clinical phase. Karo Bio is based in Huddinge, Sweden and is listed on Nasdaq Stockholm. Karo Bio publishes this information according to the Swedish Securities Market Act. The information was submitted for publication on 23 April 2015, at 8.30 a.m. CET. This press release is also available at www.karobio.se and www.newsroom.cision.com

Interim Report January - March 2015

Record high net sales and order intake – The gross margin remains low – New strategy launched First quarter 2015                                      · Order intake doubled in the quarter compared to the previous year SEK 269 (133) million. · Net sales increased by 42% to SEK 148 (104) million. · The operating profit amounted to SEK 0.9 (-9.2) million and the profit for the period amounted to SEK 1.3 (-10.0) million. · Launch of a new solution-focused strategy at the trade fairs NRF in New York in January and EuroCIS in Düsseldorf in February. · The first pilot stores equipped with new SmartFlash functionality. +----------------------------------------+--------+------+|Amounts in SEK M unless otherwise stated| Q 1| Q 1|| | 2015| 2014|+----------------------------------------+--------+------+|Order intake | 269,0| 133,0|+----------------------------------------+--------+------+|Net sales | 147,5| 103,6|+----------------------------------------+--------+------+|Gross margin1) |    24%|   21%|+----------------------------------------+--------+------+|Operating profit |    0,9| -9,2|+----------------------------------------+--------+------+|Cash flow | 42,0| 29,3|+----------------------------------------+--------+------+|Profit for the period |     1,3| -10,0|+----------------------------------------+--------+------+|Earnings per share (SEK) | 0,01| -0,09|+----------------------------------------+--------+------+ 1)       Depreciations of capitalized development costs were during 2014 reclassified from the research and development cost function to cost of goods sold. The effect of this is SEK 2.8 (2.7) million for quarter 1 2015 Comments from the CEO, Jonas VestinI am pleased to report that for the first quarter of 2015, Pricer is able to report the highest ever net sales for a first quarter. Net sales increased by 42 per cent compared to the same period last year. Further the order intake more than doubled – 102 per cent – compared to first quarter 2014. This trend creates stability for Pricer's efforts to broaden its range of products, aiming at more solution-oriented offering. However, the company's result has been burdened by continued pressure on margins. Even though the company is now reporting a profit, it is insufficient. We are therefore focusing on improving the gross margin, something that a broader and higher growth creates opportunities for. The gross margin is negatively affected by the strength of the US dollar, since the dollar is Pricer's main purchasing currency. This negative effect is not fully compensated by invoicing in dollars or by currency clauses. Measures have been implemented to balance this trend. The product mix and effect of some contracts concluded at lower margins are further reducing profit for the quarter. Through a combination of operational and strategic measures relating to how we position ourselves and price our offer, we aim at gradually improving our operating profit and gross margin. Some contracts will continue to burden the gross margin in the coming quarters. However, with a stronger cash flow, a completely new and vital organization, a high level of confidence from our customers and, not least, our commitment to solutions that respond well to retailers’ needs for a digital upgrade, we are now in a good position to achieve increasing profitability. I would like to reiterate that this combined effect is expected to give a certain positive effect on sales and operating profit in 2015 and further improvements in 2016. During the past six months, the management has focused on liquidity and tied-up capital. Pricer ends the quarter with a positive net cash position of SEK 90 million, meaning a positive cash flow of about SEK 100 million during for the last six months. Following the strong order intake, it is expected that the working capital will increase later in the year. The result for the quarter was negatively affected by investments in marketing activities, such as participation in more trade fairs than previously and increased customer and partner activities.   Pricer's system for more efficient collection of on-line orders (also called Click & Collect) and optimization of shelf space, have been success factors as Pricer's new solutions reached the market. The first pilot projects to study the effect on consumer behavior started up during the first quarter. Pricer’s ambition is to become a partner for digital solutions for the retail industry in price optimization, logistics and marketing at the shelf-edge. As in previous reports, we do not issue any forecast for 2015.

Central banks cannot fix it all

The US economy remains in expansion mode, although growth stalled temporarily during the first quarter, reflecting harsh weather conditions, labour disputes on the West Coast, and weaker net exports. However, the outlook for the remainder of the year and beyond is solid. Against that backdrop, we expect the labour market to tighten further. The Fed has so far stayed on the sidelines, bewildering analysts to some extent, but the rate hike is now probably not far away. Our view is that the Central Bank will make its first move in June. Subsequent steps will likely be very gradual. The situation in the eurozone remains starkly different. Following the ECB’s decision to embark on its quantitative easing programme, the euro weakened substantially against the dollar, while credit conditions in the troubled monetary union improved. Things in the real economy also seem to be going in the right direction, as business cycle surveys now point to a gradual recovery in economic activity. However, considering the amount of slack that still characterises large parts of the region, the ECB will have to maintain its policy stance much longer. That makes further dollar strength vis-a-vis the euro likely. Economic recoveries after the financial crisis have been slower than in the typical cyclical upswing and several European economies have hardly come back at all. But while the US recovery has been weak in terms of GDP, the labour market has bounced back strongly and unemployment has declined much more rapidly than forecast. Even so, wage inflation has remained tame. There has been a similar development in the UK and both the Fed and the Bank of England show uncertainty about when the first rate hike is due. The seeming disconnect between unemployment and wage inflation is one of the factors contributing to this uncertainty. The question is if we can base forecasts on a stable relationship between the tightness of the labour market and wage inflation or if we are in uncharted territory In China, recent data confirm that growth is decelerating. As this is mostly due to structural factors, conventional fiscal and monetary measures to support the economy may only dampen the slowdown, not stop it. However, while financial risks are present, we think that they can probably be managed, in which case China should still be able to avoid a hard landing scenario and remain an important driver for the world economy. We also continue to have a positive view on India. The Russian situation has improved marginally, mostly due to the slight bounce in oil prices, but the recession scenario is still unfolding and we have seen nothing that would change our rather gloomy take on the longer-term outlook. Similarly, Brazil’s prospects are negative too. The Nordic countries are a rather mixed bunch. Economic activity in Denmark surprised on the upside during the latter half of last year, raising hopes that conditions were improving after a number of dismal years. However, a significant improvement does not seem to be on the cards for now. Finland is in greater trouble, reflecting cyclical as well as structural factors. While voters strongly signalled their desire for changes in the election on April 19, the likely coalition t headed by the Centre Party will be forced to make quite a few tough decisions to put the struggling economy on a sounder footing. Norway seems to be slowing faster than Norges Bank expected. Another rate cut cannot be excluded. Sweden has the strongest economy among the Nordic countries. The economy looks quite different from that of the eurozone. In many ways, the cyclical situation seems more similar to that of the UK, for instance, with a limited degree of unused capacity despite nominally rather high unemployment. Nevertheless, following significantly lower inflation than forecast, the Riksbank caved in and adopted a negative policy rate. While we believe it would have been wise to follow more closely in the footsteps of Norges Bank and adopt an expansionary posture earlier, we believe there are good reasons to expect that the Riksbank will prove successful this time in eventually moving inflation closer to the official target. For further information, please contact: Jan Häggström, Chief economist, +46-8 701 10 97, +46 70 761 43 66For more information on Handelsbanken, see: www.handelsbanken.se (Please see attached PDF file for tables).

Data from OPTIMIST trials show SVR12 rates of 97 percent in HCV patients without cirrhosis and 84 percent in HCV patients with cirrhosis

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that our partner Janssen Sciences Ireland UC, today publish positive results for simeprevir, the NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL) in Vienna. Late-breaking results from the phase III OPTIMIST-1 and OPTIMIST-2 trials highlight the clinical outcomes of simeprevir in an all-oral combination regimen in a wide range of patients with hepatitis C virus (HCV) infection. The results from the OPTIMIST-1 and OPTIMIST-2 trials are the first phase III data to be presented on simeprevir in combination with sofosbuvir (SMV/SOF) in patients with genotype 1 chronic HCV infection, both with and without cirrhosis. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor developed by Gilead Sciences, Inc. OPTIMIST-1[i] · OPTIMIST-1 is a phase III, randomized, open-label trial to investigate the efficacy and safety of the all-oral regimen of SMV/SOF among treatment-naïve and treatment-experienced genotype 1 chronic HCV infected patients without cirrhosis. The primary objective was to show superior sustained virologic response (SVR) at 12 weeks after treatment (SVR12) with twelve and 8 weeks of treatment with SMV/SOF versus a historical control (patients previously treated with approved regimens containing a direct-acting antiviral, pegylated interferon and ribavirin). · Ninety-seven (97) percent of patients treated with SMV/SOF for 12 weeks (n=150/155) achieved SVR12, which was superior to the SVR12 rate of 87 percent among the historical control.- SVR12 rates of 100 percent were seen among patients with IL28B CC genotype (n=43/43) and those with baseline NS5A and NS3 Q80K polymorphisms (n=9/9). · Patients treated with eight weeks of SMV/SOF achieved an SVR12 rate of 83 percent (n=128/155), which was not superior to the SVR12 rate of 83 percent in the historical control.- High SVR12 rates were seen among patients with baseline HCV RNA IL28B CC genotype (93 percent; n=38/41), patients with genotype 1b HCV infection (92 percent; n=36/39), and patients without baseline NS5A and Q80K polymorphisms (89 percent; n=78/88). · The most frequently reported adverse events in the 12-week and eight-week treatment arms were headache (14 and 17 percent, respectively), fatigue (12 and 15 percent, respectively) and nausea (15 and 9 percent, respectively). OPTIMIST-2[ii] · OPTIMIST-2 is a phase III, open-label, single-arm trial to investigate the efficacy and safety of SMV/SOF in treatment-naïve and treatment-experienced genotype 1 chronic HCV infected patients with cirrhosis. The primary objective was to show superior SVR12 with twelve weeks of treatment with SMV/SOF versus a historical control. · Twelve (12) weeks of treatment with SMV/SOF resulted in SVR12 rates of 84 percent (n=86/103), which was superior to the SVR12 rate of 70 percent in the historical control. · Higher SVR12 rates were seen in patients with baseline NS5A polymorphisms with or without NS3 Q80K polymorphisms (100 percent, n=13/13), patients with albumin ≥4 g/dL (94 percent; n=47/50), and treatment-naïve patients (88 percent; n=44/50). · The most common adverse events were fatigue (20 percent), headache (20 percent) and nausea (11 percent).  For further information, please contact:Ola Burmark, CFO Medivir AB, mobile: +46 (0)725-480 580.Charlotte Edenius, EVP Development Medivir AB, mobile +46 (0)73-386 42 46. Medivir is required under the Securities Markets Act to make the information in this press release public.The information was submitted for publication at 10.30 CET on 23 April 2015. About Simeprevir (OLYSIO®)Simeprevir is an NS3/4A protease inhibitor which has been developed by Janssen Sciences Ireland UC in collaboration with Medivir AB. In November 2013, simeprevir was initially approved by the U.S. Food and Drug Administration, and in May 2014, it was granted marketing authorisation by the European Commission. Subsequent marketing authorisations have followed in several other countries around the world. Indications vary by market. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorisation held by Janssen-Cilag International NV. About MedivirMedivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List. ---------------------------------------------------------------------- [i] A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of treatment with simeprevir plus sofosbuvir in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: The OPTIMIST-1 study. Abstract presented at The International Liver Congress™ 2015.[ii] A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir plus sofosbuvir in treatment-naïve or –experienced patients with chronic hepatitis c virus genotype 1 infection and cirrhosis: The OPTIMIST-2 study. Abstract presented at The International Liver Congress™ 2015.

Scania Interim Report, January–March 2015

Summary of the first three months of 2015 • Operating income decreased by 1 percent to SEK 2,245 m. (2,257)• Net sales rose by 6 percent to SEK 22,321 m. (21,126)• Cash flow amounted to SEK 783 m. (730) in Vehicles and Services Comments by Per Hallberg, acting President and CEO: “Scania’s sales rose to SEK 22.3 billion and earnings for the first quarter amounted to SEK 2,245 m. Positive currency rate effects were offset by lower vehicle deliveries, mainly attributable to Latin America and Eurasia. Order bookings in Europe increased to the highest level since 2007. Scania has continued to increase its market share, among other things through a leading Euro 6 range and a broad range of engines for alternative fuels. Total order booking for trucks during the first quarter decreased somewhat compared to the previous quarter, mainly due to weaker demand in Latin America and in Eurasia. Demand in Brazil was negatively impacted by low economic activity and the new, much less attractive conditions in the subsidised financing programme (FINAME). Order bookings in Russia decreased sharply to a very low level and the outlook is uncertain. In Asia, order bookings were stable compared to the previous quarter. In buses and coaches, total order bookings were stable, with an increase in Latin America and a downturn in Asia compared to the previous quarter. In Engines, the high level of order bookings continued from the fourth quarter of 2014, driven by Latin America. Scania is continuing its long-term efforts to boost market share in Services and revenue rose to more than SEK 5 billion, supported by positive currency rate effects. However, the weak market in Russia impacted service revenue negatively. Financial Services reported operating income of SEK 256 m. Scania is continuing to strengthen its presence in Africa and Asia and expanded its operations in India during the first quarter by starting bus and coach production.” For more information please see the attached pdf. Contact personsPer HillströmInvestor RelationsTel. +46 8 553 502 26Mobile tel. +46 70 648 30 52 Erik LjungbergCorporate RelationsTel. +46 8 553 835 57Mobile tel. +46 73 988 35 57

Alfa Laval AB (publ) Interim report January 1 - March 31, 2015

Summary First three monthsOrder intake increased by 19 percent* to SEK 9,844 (7,474) million.Net sales increased by 24 percent* to SEK 9,071 (6,597) million.Adjusted EBITA was SEK 1,570 (1,062) million.Adjusted EBITA-margin was 17.3 (16.1) percent.Result after financial items was SEK 1,264 (794) million.Net income was SEK 863 (564) million.Earnings per share was SEK 2.05 (1.34).Cash flow from operating activities was SEK 1,101 (592) million.Impact on EBITA of foreign exchange effects was SEK 148 (-10) million.Impact on result after financial items of comparison distortion items was SEK - (-60) million. * Excluding currency effects. DividendThe Board of Directors propose a dividend of SEK 4.00 (3.75) per share. Outlook for the second quarter“We expect that demand during the second quarter 2015 will be somewhat lower than in the first quarter.”Earlier published outlook (February 3, 2015): “We expect that demand during the first quarter 2015 will be somewhat lower than in the fourth quarter.” The interim report has not been subject to review by the company’s auditors. For more information, please contact:Peter Torstensson, Senior Vice President, CommunicationsPhone: +46 46 36 72 31Mobile: +46 709 33 72 31 peter.torstensson@alfalaval.com Gabriella Grotte, Investor Relations ManagerPhone: +46 46 36 74 82 Mobile: +46 709 78 74 82gabriella.grotte@alfalaval.com Alfa Laval AB (publ)PO Box 73SE-221 00 LundSweden Corporate registration number: 556587-8054 Alfa Laval AB (publ) discloses the information provided herin pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 12.45 p.m. on April 23, 2015

Interim report January-March 2015

Trelleborg started the year by posting strong earnings, despite the prevailing market situation in agriculture and oil/gas. Our margin discipline negatively impacted volumes, and thus also organic sales. Despite the organic sales trend, the Group achieved the highest operating profit to date for a single quarter, partly positively impacted by currency effects. Our largest business area, Trelleborg Sealing Solutions, is developing satisfactory and reported its highest result to date for a single quarter. Acquired operations had a positive impact on earnings. The TrelleborgVibracoustic joint venture performed well and according to plan, continuing to outperform the underlying market in terms of growth. The company reported its highest operating margin to date for a single quarter. Activities aimed at preparing TrelleborgVibracoustic for a potential initial public offering are progressing. At the end of the quarter, some signs of improvement were noted in the European market in individual segments, while a slowdown was observed in a few segments in the North American market. The significantly lower world market price of oil impacts parts of the Group, and has a negative effect on demand and increases the uncertainty for our deliveries to the oil/gas industry. At the same time the lower price of oil is expected to stimulate the economy in general. Our agricultural tire operation will continue to be impacted by the challenging market situation within its segment. Our overall assessment is that the market is moving sideways. We are continuously monitoring developments and are maintaining preparedness to adjust our various businesses to fluctuating demand”, says Peter Nilsson, President and CEO. First quarterNet sales for the first quarter of 2015 increased by 14 percent (4) to SEK 6,370 M (5,597). Organic sales declined by 4 percent (increase: 3). Effects of structural changes made a positive contribution of 4 percent (0), while the effects of exchange rate movements were a positive 14 percent (pos: 1). Operating profit, excluding the participation in TrelleborgVibracoustic and items affecting comparability, rose 7 percent to SEK 833 M (779), equivalent to an operating margin of 13.1 percent (13.9). The operating profit was the Group’s highest to date for a single quarter. Items affecting comparability for the quarter amounted to an expense of SEK 35 M (expense: 18), which was fully attributable to previously announced restructuring programs. Operating profit in the quarter for TrelleborgVibracoustic, excluding items affecting comparability, increased 20 percent and amounted to EUR 46.2 M (38.6). This corresponded to an operating margin of 9.5 percent (8.6), the highest to date for the company for a single quarter. Trelleborg’s participation in TrelleborgVibracoustic’s profit amounted to SEK 137 M after tax (87). Items affecting comparability amounted to an expense of SEK 27 M (expense: 27) and is in line with communicated full-year levels. Earnings per share rose 11 percent to SEK 2.54 (2.29). The operating cash flow was SEK 59 M (367). Market outlook for the second quarter of 2015Demand is expected to be on a par with the first quarter of 2015, adjusted for seasonal variations. For further information, please contact:Media: Vice President Media Relations Karin Larsson, +46 (0)410 67015, +46 (0)733 747015, karin.larsson@trelleborg.comInvestors/analysts: Vice President IR Christofer Sjögren, +46 (0)410 67068, +46 (0)708 665140, christofer.sjogren@trelleborg.com This is information of the type that Trelleborg AB (publ) is obligated to disclose in accordance with the Swedish Securities Exchange and Clearing Operations Act and/or the Financial Instruments Trading Act. The information was issued for publication on Thursday, April 23, 2015, at 13:00 CET.

RESULTS OF PHASE 1 STUDY OF BETALUTIN™ IN PATIENTS WITH NON-HODGKIN LYMPHOMA TO BE PRESENTED AT THE INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

Oslo, Norway, 23 April 2015: Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology, announces that results of its Phase 1 clinical study of Betalutin™ in patients with relapsed CD37+ Non-Hodgkin Lymphoma (NHL) will be presented at the International Conference on Malignant Lymphoma (13-ICML) that will take place on June 17 -20 in Lugano, Switzerland. Data and analysis will be presented in a poster on June 18 and 19 by Dr Arne Kolstad, Senior Consultant in Medical Oncology and Radiation Therapy at the Oslo University Hospital, Norwegian Radium Hospital, the study’s Principal Investigator. Betalutin™ comprises a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). Preliminary data from the study, presented at the American Society of Hematology Conference in December 2014, demonstrated Betalutin™’s promising efficacy and safety profile. Based on these results, Nordic Nanovector is advancing the clinical development of Betalutin™ in both relapsed/refractory CD37+ follicular lymphoma and relapsed/refractory CD37+ diffuse large B-cell lymphoma using proceeds from its recently complete initial public offering and previous fundraisings. Betalutin™ has orphan-drug designation for treatment of follicular lymphoma in the US and Europe. For further information, please contact:Luigi Costa, CEO, or Tone Kvåle, CFOTel: +47 22 18 33 01ir@nordicnanovector.com  Media Enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44 207 282 2948mark.swallow@citigatedr.co.uk Knut Ekern (Gambit Hill & Knowlton)  Tel: +47 22 04 82 00knut.ekern@hkstrategies.com  About Nordic NanovectorNordic Nanovector is a biotech company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radio-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of Non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin™ comprises a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It has shown promising efficacy and a favourable safety profile in Phase 1 studies in a difficult-to-treat NHL patient population. Betalutin™ is fast advancing through clinical development for the treatment of major types of NHL with first approval anticipated in 2018. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialization of Betalutin™ in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat a number of select cancer indications. Further information about the Company can be found at www.nordicnanovector.com Forward-looking statementsThis announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector’s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise BetalutinTM, technology changes and new products in Nordic Nanovector’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Scientists create the sensation of invisibility

The history of literature features many well-known narrations of invisibility and its effect on the human mind, such as the myth of Gyges’ ring in Plato’s dialogue The Republic and the science fiction novel The Invisible Man by H.G. Wells. Recent advances in materials science have shown that invisibility cloaking of large-scale objects, such as a human body, might be possible in the not-so-distant future; however, it remains unknown how invisibility would affect our brain and body perception. In an article in the journal Scientific Reports, the researchers describe a perceptual illusion of having an invisible body. The experiment involves the participant standing up and wearing a set of head-mounted displays. The participant is then asked to look down at her body, but instead of her real body she sees empty space. To evoke the feeling of having an invisible body, the scientist touches the participant’s body in various locations with a large paintbrush while, with another paintbrush held in the other hand, exactly imitating the movements in mid-air in full view of the participant. “Within less than a minute, the majority of the participants started to transfer the sensation of touch to the portion of empty space where they saw the paintbrush move and experienced an invisible body in that position,” says Arvid Guterstam, lead author of the present study. “We showed in a previous study that the same illusion can be created for a single hand. The present study demonstrates that the ‘invisible hand illusion’ can, surprisingly, be extended to an entire invisible body.” The study examined the illusion experience in 125 participants. To demonstrate that the illusion actually worked, the researchers would make a stabbing motion with a knife toward the empty space that represented the belly of the invisible body. The participants’ sweat response to seeing the knife was elevated while experiencing the illusion but absent when the illusion was broken, which suggests that the brain interprets the threat in empty space as a threat directed toward one’s own body. In another part of the study, the researchers examined whether the feeling of invisibility affects social anxiety by placing the participants in front of an audience of strangers. “We found that their heart rate and self-reported stress level during the ‘performance’ was lower when they immediately prior had experienced the invisible body illusion compared to when they experienced having a physical body,” says Arvid Guterstam. “These results are interesting because they show that the perceived physical quality of the body can change the way our brain processes social cues.” The researches hope that the results of the study will be of value to future clinical research, for example in the development of new therapies for social anxiety disorder.   “Follow-up studies should also investigate whether the feeling of invisibility affects moral decision-making, to ensure that future invisibility cloaking does not make us lose our sense of right and wrong, which Plato asserted over two millennia ago,” says principal investigator Dr. Henrik Ehrsson, professor at the Department of Neuroscience. This research was funded by the Swedish Research Council, and the Söderberg Foundation. Publication: ‘Illusory ownership of an invisible body reduces autonomic and subjective social anxiety responses (http://nature.com/articles/doi:10.1038/srep09831)’, Arvid Guterstam, Zakaryah Abdulkarim & Henrik Ehrsson, Scientific Reports (http://www.nature.com/srep/index.html) online 23 April 2015, doi:10.1038/srep09831.

Nederman Holding AB’s AGM

The AGM of Nederman Holding AB (publ) took place on 22 April 2015. A total of 8,559,979 shares were represented at the meeting, equivalent to 73.3% of all outstanding shares. The meeting approved the Board and CEO’s proposal for a shareholder dividend for 2014 of SEK 4.0 per share. The income statement and balance sheets were adopted and the Board’s proposal for appropriation of profits was approved. The meeting approved Board fees for 2015 to be unchanged and are as follows: a fixed fee of SEK 1,400,000, of which SEK 400,000 to the Chairman of the Board and SEK 200,000 to each of the other AGM elected Board members, with the exception of the CEO. Susanne Pahlén Åklundh, Fabian Hielte, Ylva Hammargren, Per Borgvall, Gunnar Gremlin and Sven Kristensson were re-elected as Board members. Jan Svensson was re-elected as the Chairman of the Board. The AGM elected a new accounting firm, Ernst & Young AB, until the end of the AGM 2016 with authorized public accountant Staffan Landén as the main accountant until further notice. Sven Kristensson, President and CEO, NedermanTel: +46 (0)42 18 87 00email: sven.kristensson@nederman.com Stefan Fristedt, CFOTel: +46 (0)42 18 87 00email: stefan.fristedt@nederman. (stefan.fristedt@nederman.se)com Facts about NedermanNederman is one of the world's leading companies supplying products and solutions in the environmental technology sector focusing on industrial air filtration. The company's products and systems contribute to reducing the environmental effects from industrial production, to creating safe and clean working environments and to boosting production efficiency. Nederman's offering encompasses everything from the design stage through to installation, commissioning and servicing. Sales are carried out via subsidiaries in 30 countries and distributors in over 30 countries. Nederman develops and produces products at its own manufacturing and assembly units in Europe, North America and Asia. The Group is listed on Nasdaq OMX, Stockholm and has around 1,950 employees. Nederman Holding AB (publ), P.O. Box 602, SE-251 06 Helsingborg, Sweden. Corporate registration number: 556576-4205

Report from the AGM of Alfa Laval AB

This is an unofficial translation of the Swedish report. In case of any discrepancies between the Swedish report and this English translation, the Swedish version shall prevail.         At the meeting, Lars Renström, President and CEO, summarized Alfa Laval’s development in 2014, a year which – despite waning optimism regarding the global economy – resulted in very strong order intake and sales. Contributing to the positive development was among others, a very strong order intake from the ship building industry as well as a very good demand from areas relating to oil and gas. Furthermore, he talked about Alfa Laval’s biggest acquisition, that of Frank Mohn AS – a Norwegian supplier of pumping systems for the marine industry and offshore market. Lars Renström’s entire speech can be found on:”www.alfalaval.com/investors”. The income statements and balance sheets were adopted, together with the Board’s proposal for distribution of surplus. The proposed dividend of SEK 4:00 per share was approved. The AGM also approved discharge from liability for the members of the Board of Directors and the Managing Director. As Board members Gunilla Berg, Ulla Litzén, Anders Narvinger, Arne Frank, Finn Rausing, Jörn Rausing, Ulf Wiinberg and Lars Renström were re-elected. Anders Narvinger was appointed Chairman of the Board. Björn Hägglund had declined re-election. Instead, Margareth Øvrum was elected new member. Margareth Øvrum holds a Master of Science in Technical Physics and is a member of the Executive Committee of Statoil ASA since 2004. The Nomination Committee’s proposal regarding auditors was also adopted and authorized public accountants Helene Willberg and Håkan Olsson Reising were re-elected as ordinary auditors for the coming year. The authorized public accountants David Olow and Duane Swanson were re-elected deputy auditors. The AGM decided to adopt the remuneration to the Board of Directors for 2015 in line with the Nomination Committee’s proposal. Remuneration amounts to SEK 4,850,000, an increase from SEK 4,575,000 in 2014. Additional remuneration will be paid for work performed in the Board’s committees. Furthermore the AGM adopted a resolution on the guidelines for compensation to senior management, including fixed compensation as well as long and short term variable compensation. Complete proposals can be found on www.alfalaval.com. Lund, April 23, 2015 Alfa Laval AB (publ.) For more information please contact: Peter TorstenssonVice President, CommunicationsAlfa LavalTel: + 46 46 36 72 31Mobile: +46 709 33 72 31 Gabriella GrotteInvestor Relations ManagerAlfa LavalTel: +46 46 36 74 82Mobile: +46 709 78 74 82

Press release from Trelleborg AB’s 2015 Annual General Meeting

Trelleborg AB’s Annual General Meeting was held on April 23, 2015 in Trelleborg. Approximately 670 shareholders attended the Meeting. The theme of President and CEO Peter Nilsson’s address was “Continued focus on leading positions in selected segments”. The presentation summarized the Group’s direction and strategic work to secure leading positions in selected segments and focused on different dimensions of how Trelleborg improves and increases value creation for customers. Peter Nilsson also reported on the 2014 fiscal year and progress in the first quarter of 2015. A video of the President and CEO’s address at the Meeting (Swedish only), together with a transcript (Swedish and English), will be available shortly at www.trelleborg.com. The Annual General Meeting resolved on the following: DividendIn accordance with the proposal of the Board of Directors and the President, the Annual General Meeting resolved to pay a dividend of SEK 3.75 per share (3.25). The record date is April 27, which means that the dividend is expected to be distributed by Euroclear Sweden AB on April 30. Income statement and balance sheetThe Meeting adopted the income statement and balance sheet, and the consolidated income statement and balance sheet for 2014. The members of the Board and the President were discharged from personal liability for the 2014 fiscal year. Board of Directors and auditorThe Meeting resolved to expand the Board by one member to encompass nine members. In accordance with the Nomination Committee’s proposal, Hans Biörck, Jan Carlson, Claes Lindqvist, Sören Mellstig, Peter Nilsson, Bo Risberg, Nina Udnes Tronstad and Heléne Vibbleus were re-elected. Anne Mette Olesen was elected as new Board member. The Meeting elected Sören Mellstig as Chairman of the Board. The Company’s auditor, PricewaterhouseCoopers, with Mikael Eriksson as auditor in charge, was re-elected for the period until the close of the 2016 Annual General Meeting.            Remuneration and remuneration principlesIn accordance with the Nomination Committee’s proposal, the Meeting decided that the total fees paid to the Board, excluding travel expenses, be SEK 4,625,000 (3,760,000), with SEK 1,300,000 (1,150,000) to be paid to the Chairman and SEK 475,000 (435,000) to be paid to each of those Board members elected by the Annual General Meeting who are not employed within the Trelleborg Group. The Meeting decided that the auditor’s fees be paid on a current account basis. In addition, the Meeting decided that fees paid to the members of the Audit Committee be SEK 150,000 (150,000) for the Chairman and SEK 100,000 (100,000) each for other members and that fees paid to members of the Remuneration Committee be SEK 50,000 (50,000) for each member. The Meeting also decided that fees paid to members of the Finance Committee be SEK 50,000 (50,000) for each member. In accordance with the Board’s proposal, the Meeting approved the remuneration principles for the President and senior executives. Decision on the Nomination CommitteeThe Annual General Meeting approved the nomination process for the Nomination Committee as presented. Minutes from the Annual General Meeting will be published on www.trelleborg.com.

Bravida acquires Peko Group and expands to Finland

With the acquisition, Bravida meets its strategic plan to establish operations in all Nordic countries.– To expand in Finland is a central part of our strategic plan for growth. Peko Group is a strong and well-managed company active in all our fields of technology. With the acquisition of Peko Group, we have reached an important milestone to establish local operations in the market. Our long-term ambition is to achieve further growth in Finland, says Mattias Johansson, CEO Bravida.Peko Group’s offer includes installation and service solutions within the electrical, heating and plumbing, as well as the HVAC field. With head quarters in Tampere, the company holds a strong position in southern and central Finland. The company is established in the Helsinki region as well.Peko Group’s operational business will become the new Bravida division in Finland. Marcus Karsten has been appointed CEO of Bravida Finland as well as new Division Manager. Previously, Karsten was the president of the technical building services division of Lemminkäinen Talotekniikka Oy. His team is now developing the new division in Finland, using Peko Group as a foundation.– Bravida is a quality brand and a successful multitechnical service provider to the Scandinavian market. The Company wants to be an influential player in the on-going consolidation of the Finnish market. We offer a strong new option for technical building services and maintenance, says Marcus Karsten, head of Bravida Finland.The acquisition will require regulatory approvals from the Finnish competition authority.For further information, please contact:Mattias Johansson, CEO and Group President Bravida. Phone: +46 8 695 20 00Staffan Påhlsson, Senior Vice President Bravida, Phone: +46 8 695 20 00Marcus Karsten, CEO and Division Manager Bravida Finland, Phone +358 400 792 327

Haldex interim report, January - March 2015

Good cost control combined with sales growth led to yet another quarter of improved profitability. Net sales for Q1 totaled SEK 1,246 (1,041) m, equivalent to growth of 20% compared with the same period previous year. However, net sales were impacted by major exchange rate fluctuations. After currency adjustments, net sales increased by 2%. Operating income for Q1 excluding one-off items amounted to SEK 115 (84) m, which is equivalent to an operating margin of 9.3 (8.1)%. Including one-off items, operating income was SEK 114 (83) m and the operating margin was 9.2 (7.9)%. The net income after tax for Q1 totaled SEK 79 (48) m and the earnings per share for Q1 totaled SEK 1.78 (1.03). Cash flow from operating activities for Q1 totaled SEK 2 (3) m. The Board of Directors of Haldex proposes to the annual general meeting that a dividend of SEK 3.00 (2.00) per share be distributed with the record date on April 30 and the payout date on May 6.   Key figures for January - March 2015(same period previous year in brackets) ·Net sales, SEK m   1,246 (1,041) ·Operating income, excl. one-off items, SEK m   115 (84) ·Operating income, SEK m   114 (83) ·Operating margin, excl. one-off items, %   9.3 (8.1) ·Operating margin, %   9.2 (7.9) ·Return on capital employed, excl. one-off items,%1    22.4 (16.1) ·Return on capital employed,%1   13.5 (9.4) ·Net income, SEK m   79 (48) ·Earnings per share, SEK   1.78 (1.03) ·Cash flow, operating activities, SEK m   2 (3) 1) Rolling twelve months   Comment from Bo Annvik, President and CEO: “We got off to a good start in 2015 with a quarter of growth and continuing profitability improvement. Profitable growth is at the top of the agenda this year. We created a stable platform over the past years, which increased cost effectiveness. We also have a strong market position, which as a whole creates good prospects for profitable growth. Success for disc brakes In 2014, we laid the foundations for continuing expansion in disc brakes and we saw a substantial increase in sales from this product group in Q1 2015. We are currently working on taking advantage of our strong position in Trailer in order to win new customer contracts in Truck. Broadening our product portfolio to launch versions of the disc brake for heavier trucks is in the pipeline. Our disc brake sales are mainly in Europe and it is difficult to estimate when sales will take off in the U.S. I visited the Mid-America Trucking Show in March and it is clear that the disc brake technology is next in line in the U.S. The great majority of the brakes on display at the show are disc brakes, even though in practice only a very small portion is sold. We are currently planning to relaunch our disc brake in the U.S. after being outside of the market due to a patent dispute. In March 2016, will once again be able to actively sell and market disc brakes on the U.S. market, and given the interest we have observed, we see the second quarter 2016 as a good time to initiate customer discussions again. Delayed maintenance affecting aftermarket The winter has been long and hard in North America. The period when many fleets service their vehicles is normally in Q1, but this year we are seeing this period begin later than last year. One part of our business that has been affected substantially is our North American Reman operations, where products are remanufactured and resold in mint condition. We estimate that maintenance work has been postponed slightly, but that the aftermarket is also slightly weaker than the past year. Field inspection according to plan Our long-term vision is for Haldex products to have zero errors. We are working very hard to constantly improve our operations and are already operating at a high level. In spite of this, a warranty case emerged in North America in late 2014 requiring much attention in the form of a field inspection and product replacements. All of the disc brakes of the relevant product type we and our customers have in stock were inspected in Q1. In addition, the field inspection is proceeding according to plan and is estimated to continue throughout 2015. I have personally visited our largest customers in North America and had a good, active dialogue concerning our future business relationship. I estimate that we will lose some revenues in the short term due to this product error, but that we will continue in the long term to build on the customer relationships we have had for many years. Restructuring program We have had an ongoing restructuring program since 2013. We wrapped up the union negotiations involving the final part of the plan at the end of the past year – moving production capacity from Germany to Hungary. We successfully moved the first product line to Hungary in Q1 this year, and I am glad to see that the process is effective and well organized. The move of the remaining product lines are planned to continue throughout 2015. Opening of the MIRA R&D center The construction of our new R&D center at MIRA had been in progress for one year, and the center was officially opened in Q1. MIRA is a test track just outside of Birmingham, UK, and we have now successfully co-located development and testing resources in the same building, adjacent to the test track, leading to better and more effective product development. Outlook for 2015 2014 was a testament to our ability to profitably grow faster than the market and we will tirelessly continue onward in this direction in 2015. in addition to organic growth, we are also interested in complementary acquisitions. Our market position is positive overall, but since production volumes are already at a high level, the relative growth rates on the market are expected to be lower than what we saw in 2014. The number of trucks produced during the year is expected to increase in both North America and Europe, even though we estimate that North America may gradually slow down in the second half of the year. It is good news that India's economy has begun to recover and we had solid sales in that region in Q1. However, South America and China are facing a challenging time with the majority of truck manufacturers significantly reducing their production. However, it is still a positive market to operate on overall, which gives us good prospects for a solid year in 2015.”   Full interim report The full interim report is available at http://www.haldex.com/financialreports or at http://news.cision.com/haldex Press and analyst meeting Media and analysts are invited to a telephone conference at which the report will be presented with comments by Bo Annvik, President and CEO, and Andreas Ekberg, CFO. The presentation will also be webcasted live and you can participate with questions by telephone. Date & Time: Monday April 27 at 15.00 CEST The press conference is broadcasted at: http://edge.media-server.com/m/p/oee45wtn To join the telephone conference: Sweden: +46 8 505 564 74UK: +44 203 364 5374Denmark: +45 354 455 80USA: +1 855 753 2230 The webcast will also be available afterwards and you can download the Interim report and the presentation from Haldex website: http://www.haldex.com/financialreports  Haldex AB (publ) is required to publish the above information under the Swedish Financial Instruments Trading Act. The information was submitted for publication on April 24, 2015 at 7.20 am CEST.

Saab Signs Contract with Brazil on Weapon Acquisition for Gripen NG

The weapon acquisition contract includes weapon deliveries by Saab and suppliers which have been selected by the customer, for the Brazilian Gripen aircraft. The weapon deliveries will be made in relation to deliveries of the Gripen NG aircraft to the Brazilian Air Force. The contract supplements the existing contract with Brazil concerning development and production of 36 Gripen NG, which was announced on 27 October 2014. The effectiveness of the weapon acquisition contract is subject to fulfillment of certain conditions. These include, among others, necessary export control-related authorisations. All conditions are expected to be fulfilled during the second half of 2015. For further information, please contact: Saab Press Centre, +46 (0)734 180 018, presscentre@saabgroup.com www.saabgroup.com www.saabgroup.com/YouTube Follow us on twitter: @saab Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs.  The information is that which Saab AB is required to declare by the Securities Business Act and/or the Financial instruments Trading Act. The information was submitted for publication on 24 April 2015 at 07.45 (CET).

President and CEO Keith McLoughlin’s comments on the results for the first quarter 2015.

Results in Major Appliances EMEA continued to strengthen and the EBIT margin improved to 4.3% in the first quarter of 2015 compared to 1.8% a year ago. Earnings in Major Appliances Asia/Pacific and Professional Products also increased. As previously communicated, the operating income for Major Appliances North America was negative for the first quarter, mainly due to the challenges within refrigeration and freezers following new energy requirements. Operations in Latin America continued to perform well in a weakening market environment. The Group’s operating income amounted to SEK 516 million for the first quarter of 2015. A strong product mix, with focus on high-margin categories such as built-in kitchen products, contributed to a positive organic growth in Major Appliances EMEA. In parallel, the cost-savings programs previously initiated impacted earnings positively. Overall market demand in Europe stabilized and increased by 1% in the quarter. The UK and Germany showed particular strength, while the Russian market declined sharply. Excluding Russia, the market grew by 4%. The European market for appliances is expected to grow by 1–2% in 2015. Electrolux operations in North America continued to be negatively impacted by the transition of the product ranges within refrigeration and freezers. This transition is a consequence of the new energy requirements imposed during the second half of 2014. Earnings were also affected by the ramp up of the cooking plant in Memphis, which has been slower than anticipated. A program to restore profitability and increase efficiencies in production is under way. It will require most of 2015 before actions taken will show full effect. We expect full-year market growth in North America to be towards the lower end of the previously communicated range of 3-5%. The market environment in Latin America has been challenging. Demand for appliances deteriorated in the quarter, which also affected our sales volumes. However, continued price increases in combination with cost savings largely mitigated the deterioration in the market. Although the quarterly results were weaker compared with a year ago, our organization in Latin America has been well prepared to take timely actions. The macro-economic outlook for the region has weakened in the past few months, particularly for Brazil, and market growth for appliances remains uncertain. Earnings in Asia/Pacific improved, driven by higher sales volumes in Southeast Asia and Australia, and increased cost efficiency. The integration of the recently acquired business BeefEater, an Australian barbecue producer, has proceeded well.  In 2015, Electrolux is continuing to launch new product ranges with innovative features and designs, with the goal of being at the forefront in the market for appliances. Furthermore, work to strengthen cost efficiency through a higher degree of common platforms and through modularization in production flows is proceeding well. These are important areas for future profitable growth for Electrolux. The preparation work for the integration of GE Appliances is progressing well and according to plan. In addition to synergies of USD 300 million that were initially communicated, we have identified further synergies of USD 50 million, mainly within purchasing. We anticipate that a closure of the acquisition will be completed during the year. The acquisition is expected to strongly contribute to the achievement of the Electrolux vision of being the best appliance company in the world as measured by our customers, employees and shareholders. Stockholm, April 24, 2015 Keith McLoughlin President and CEO

Sectra to acquire partner in Denmark

it-mark primarily delivers services for managing medical images (PACS) via the Internet – so-called cloud solutions. Its customers are mainly located in Denmark, as well as other countries in the EU. The company is the largest supplier of online imaging services for private healthcare providers in Denmark. it-mark has 11 employees and its sales for 2014 amounted to DKK 13.4 million (corresponding to approximately SEK 16 million). “Sectra’s core business encompasses medical IT systems for image management that contribute to more efficient healthcare. it-mark has delivered Sectra PACS as a cloud service and has extensive knowledge of the requirements imposed by Danish healthcare customers. The acquisition will strengthen our operations in Denmark significantly,” says Petter Østbye, head of Sectra’s sales companies for medical IT operations in Scandinavia. The acquisition is in line with the Sectra Group’s strategy to expand in areas and regions where the company commands an established position, primarily through organic growth supplemented by minor acquisitions to further strengthen this organic growth. The operations will become part of Sectra’s Imaging IT Solutions business area, which develops and sells IT solutions and services that enable medical images to be managed efficiently and securely. The acquisition will not have a material impact on Sectra’s sales or earnings. It will be financed through Sectra’s own funds. The transaction includes a cash consideration and an additional purchase consideration. Sectra will take over the company on April 30, 2015 and the operations will be consolidated into the Sectra Group as of May 2015. For more information about it-mark, visit: http://www.it-mark.dk/ This information is such that Sectra must publish in accordance with the Securities Market Act. The information was issued for publication on April 24, 2015, at 8:30 a.m. (CET).

Press release from Pricer AB’s Annual General Meeting 2015

At Pricer AB’s (publ) annual general meeting on April 23, 2015, the following was resolved: · to adopt the income statement and the balance sheet, and the consolidated income statement and the consolidated balance sheet · to carry the funds at the annual general meeting’s disposal forward · to grant discharge from liability for the members of the board of directors and the Managing Directors · to amend the articles of association to elect the Company’s auditor until the end of the first annual general meeting held after the year the auditor was elected · that the board of directors shall consist of six (6) members · to re-elect Bo Kastensson, Hans Granberg, Bernt Ingman and Jan Rynning, and to elect Olof Sand and Christina Åqvist, as members of the board until the time of the end of the next annual general meeting. Bo Kastensson was re-elected as chairman of the board · that remuneration to the board, until the time of the end of the next annual general meeting, will be SEK 450,000 for the chairman and SEK 200,000 for other members not employed by the company · to elect the auditing firm Ernst & Young AB as auditors until the time of the end of the next annual general meeting · that fees to the auditors, for the period until the end of the next annual general meeting, shall be paid in accordance with invoicing approved by the company · to adopt the nomination committee’s proposal of principles for formation of nomination committee · to approve the board’s proposal regarding remuneration guidelines for the group management · to adopt a warrant program comprising certain members of the management whereby a maximum of 950,000 warrants are issued, each warrant entitling the holder to subscribe for one share in Pricer AB during the period from and including 29 May 2018 up to and including 29 June 2018 at a subscription price corresponding to 152 per cent of the volume-weighted average price of the Pricer share on Nasdaq Stockholm during the period from and including 12 May 2015 up to and including 28 May 2015 · to approve the board’s proposal regarding authorisation to issue new shares · to approve the board’s proposal regarding authorisation to resolve on acquisition of the company’s own shares Complete proposals pertaining to the annual general meeting's resolutions above are available on Pricer’s website, www.pricer.com For further information, please contact:Jonas Vestin, CEO, Pricer AB or Helena Holmgren, CFO: +46 8 505 582 00 In its capacity as issuer, Pricer AB is releasing the information in this press release in accordance with the Swedish Securities Exchange Act (2007:528). The information was distributed to the media for publication at 8.50 hrs CET on Friday, April 24th, 2015. Pricer is the global leader in providing in-store shelf-edge digital solutions that enhance both store performance and the shopping experience. Pricer’s infrared ESL platform is fast, robust, interconnectable and scalable. Pricer’s range of holistic solutions are all built on this intelligent and flexible platform, and have been stacked according to the five major retail tenants they support: •    Price – guarantee price integrity to optimize sales and margins•    Performance – make operations more efficient and compliant; speed, agility, excellence, etc.•    Promotion – tailor and enhance promotions both digitally and physically at the shelf•    Personalisation – manage and improve your customers’ shopping experience•    Prediction –use Big Data to help your customers and your store’s performance Pricer, founded in 1991 in Uppsala, Sweden, offers the most secure and fastest in-store shelf-edge communications solution. Pricer works with the world’s top retailers, small and large alike: grocers, DIY, electronics and speciality stores. Today, over 13 000 stores of the leading retailers worldwide are installed with Pricer’s leading platform. Pricer AB (publ.) is quoted on the Nordic Small Cap list of OMX. For further information, please visit www.pricer.com

IK Investment Partners to sell SportGroup to Equistone

With over 40 years’ experience, SportGroup is a worldwide quality and innovation leader for synthetic sport and recreational surface systems with turnover of approx. MEUR 300 in 2014. SportGroup develops, produces and installs artificial turf fields and tracks (both running tracks and multi-purpose surfaces). The Group operates an integrated business model with all system critical components being manufactured in-house. SportGroup has production facilities in Europe, North America and Asia-Pacific with approx. 1,000 employees worldwide. During IK’s ownership, the Group has successfully completed add-on acquisitions in Sweden, France, USA and Australasia to expand its operations and further shape its global footprint. Today, SportGroup has a strong sales network consisting both of own sales teams and dedicated partners, in over 70 countries, and a strong global customer base, with over 7,000 artificial turf pitches and over 16,000 tracks installed worldwide. SportGroup regularly sets new standards and the Company’s reference projects include the Olympics Games (Beijing, London, Rio de Janeiro) among other leading sport events. SportGroup thereby addresses the long-term market trends of increasing penetration rates of artificial turf and recreational surfaces worldwide. “Since being acquired by IK the size of the Company has doubled and the global footprint has significantly improved. The challenging market situation that we faced in 2012 triggered a transformation of SportGroup, and alongside IK, we actively invested in product innovations and brand strategy, as well as in sales and organisational excellence in order to best serve the global market trends. Today, we are the optimal positioned player in the sports surfaces industry, and we are pleased to be entering into a partnership with Equistone to support the Group’s future strategic development and growth,” said Frank Dittrich, CEO of SportGroup. “SportGroup has transformed from being a European actor into a worldwide leading specialist with a unique global footprint. Moreover, the Group has a well-balanced product range, a firm focus on innovations, and a strong product development pipeline; all which will enable further growth, and form a strong basis for the future development of the Group. We would like to thank the management team for their contribution, and wish SportGroup and its employees the very best for the future,” said Detlef Dinsel, Managing Partner at IK and advisor to the IK 2000 Fund. Completion of the transaction is subject to legal and regulatory approvals.

Insurance and finance websites can benefit from free financial tools and calculators

The tools have been improved so now: · All results are displayed on screen and not via Javascript alerts · All results appears as text and not in form boxes · The tools are responsive - so work on a mobile devices · CSS styled buttons have been added The plugin includes the following calculators: · Finance: Credit Card Calculator · Finance: Loan Calculator · Finance Calculator · Finance: Budgeting Calculator · Investment: Investment Calculator · Savings: Savings Calculator · Life Insurance: Life Cover Calculator · Mortgage: How Much Can I Borrow? · Mortgage: What Will It Cost? · Mortgage: Monthly Mortgage Payments Jason Hulott, Director at Speedie Consultants says: “Having financial tools and calculators on a website can really help enhance any finance or insurance business. It can educate and help potential customers and site visitors, as well as empower them to make smart decisions. “We have found that providing truly useful - and free - tools often helps clients and visitors to achieve a greater return on their websites, as it engages with users and keeps them on the site longer”. Jason adds that businesses looking to develop a bespoke plugin or tool for their website should get in touch. He says: “It doesn’t have to work with Wordpress, we can develop tools for any site or platform. “We are also looking to expand our range of tools, so, if there is a calculator you feel we are missing and which would be beneficial, we would love to hear from you. Or if you want something designed and built specifically for your own website we can do that too”. The suite of tools – worth £1,000 - can be accessed here: http://www.speedieconsulting.co.uk/free/wp-calculators/ Ends

New Leksell Gamma Knife to benefit more patients with brain disease

BARCELONA, April 25, 2015 – With the introduction of Elekta’s new Leksell Gamma Knife® Icon™, the benefits of precision cranial radiosurgery are now available for more patients with a wider variety of tumor types and sizes. This latest generation stereotactic radiosurgery system for the brain, integrates advanced motion management, dose delivery and imaging technologies, significantly increasing the versatility of Gamma Knife radiosurgery. Elekta unveiled Leksell Gamma Knife Icon today at the 3rd ESTRO Forum in Barcelona. “This is great news for patients,” says Niklas Savander, Elekta President and CEO. “With the new functionality in Leksell Gamma Knife Icon, doctors will have even greater flexibility in how radiosurgery is delivered, in addition to more assurance about the radiation dose and how accurately it’s targeted. This new Leksell Gamma Knife will further strengthen our leading position in radiosurgery and hopefully address some of the more complex brain disorders from which many people suffer.” Icon provides this increased flexibility by allowing physicians to choose either frame-based or frameless methods to immobilize the patient’s head, in addition to the option to perform the treatment in a single session or multiple sessions (fractions or hypofractionation). The system even enables clinicians to choose the degree of precision needed for each patient’s case – ranging from traditional radiosurgery accuracy to ultra-precise microradiosurgery. “With Leksell Gamma Knife Icon, we expect two major changes,” says Professor Jean Régis, a neurosurgeon and Gamma Knife program director at University Hospital La Timone (Marseilles, France). “First, the system will increase indications, in the sense that we will be able do more hypofractionation. The second great benefit of Icon is the ability to do true adaptive radiosurgery both interfraction and intrafraction. It has the capacity to detect and measure position changes – to automatically propose dose planning adaptation – while providing the operator with an estimate of the influence of these corrections for validation." Elekta developed Icon to be the preferred modality to treat almost any intracranial target. It offers new functionality familiar to radiation oncologists, such as cone beam CT, which should help increase the adoption of radiosurgery. By being attractive to more clinics, more patients will have access to the benefits of precision cranial radiosurgery. Maurits Wolleswinkel, Executive Vice President Neuroscience at Elekta, says: “By giving doctors greater clinical flexibility and precision, it should also give patients greater confidence and peace of mind. This system is intended to give physicians the ability and confidence to treat virtually any pathology found in the brain with the highest precision and certainty, and the efficient workflows that will allow them to do this every day in the clinic,” he says. Leksell Gamma Knife Icon is not for sale or distribution in the US and is not CE marked. # # # For further information, please contact:Gert van Santen, Group Vice President Corporate Communications, Elekta ABTel: +31 653 561 242, e-mail: gert.vansanten@elekta.comTime zone: CET: Central European TimeTobias Bülow, Director Financial Communication, Elekta ABTel: +46 722 215 017, e-mail: tobias.bulow@elekta.comTime zone: CET: Central European Time The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 10:15 CET on April 25, 2015.About ElektaElekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.

Report for the first quarter of 2015

Comments by the CEO SSAB’s operating profit for the first quarter of 2015 was SEK 564 million (excluding items affecting comparability), up SEK 446 million compared with the fourth quarter of 2014 and up SEK 530 million (pro forma) compared with the first quarter last year. This improvement was primarily driven by lower costs of raw materials, the synergies achieved from the acquisition of Rautaruukki and positive currency effects. SSAB Europe showed the strongest improvement in performance. Operating cash flow for the first quarter was SEK 784 million, despite the build-up of steel slabs ahead of the relining of the blast furnace in Luleå in summer this year. In the Nordic region and the rest of western Europe, demand for standard steel normalized compared with the decrease in demand seen towards the end of 2014. Demand for our special steels remained stable, albeit at a low level and with major geographical variations. In North America, the steel market was relatively weak during the first quarter. This was driven by high inventory levels at distributors and continued high volumes of imports from Asia and Europe. Overall, this put pressure on prices in the North American market. The costs of raw materials, primarily iron ore for the Swedish and Finnish mills, continued to fall during the quarter. Apparent use of steel is expected to increase both in Europe and in North America during 2015. Despite weak deliveries to distributors in North America during the first quarter, underlying demand remains good. However, destocking in North America has lasted longer than expected, and demand is not expected to pick up until the end of the second quarter We are now in a period where we are implementing actions included in the plan to integrate Rautaruukki. Re-negotiated purchase agreements is one of the measures we have taken that are already reflected in the result. During the first quarter, we achieved synergies of around SEK 100 million and at the end of the quarter, annual sustainable savings amounted to approximately SEK 450 million. During the spring, SSAB is undertaking one of its largest marketing efforts ever with the launch of the new brand Strenx, which consists of SSAB’s top products within structural steel which were earlier sold under the Optim, Weldox and Domex brands. GreenCoat, a new brand for SSAB’s colour-coated products, was launched in the beginning of April. These launches are two major steps toward a common product portfolio within SSAB. This information is such that SSAB must disclose in accordance with the Securities Markets Act. The information was submitted for publication on April 27, 2015 at 07.30 am. Invitation to SSAB’s first quarter 2015 results briefing SSAB invites you to a presentation of the quarterly report at 09.30am CEST on Monday April 27, 2015. The interim report for the first quarter of 2015 will be presented by SSAB’s President and CEO Martin Lindqvist, and CFO Håkan Folin. The press conference will be held in English and live webcast on SSAB’s website www.ssab.com. It is also possible to participate in the briefing via telephone. Venue and time of briefing: World Trade Center (WTC) Stockholm, Kungsbron 1, Conference room Manhattan, 09.30am CEST. Telephone numbers: +46 8 5055 64 74 (Sweden), +44 203 364 53 74 (UK), +1 855 753 22 30 (USA). Link to webcast: Go to webcast (http://edge.media-server.com/m/p/yzrmxpbm) Instructions on how to participate in the webcast will be available on SSAB’s website, including presentation material for downloading. For further information: Andreas Koch, Director IR and Financial Communications, Tel. +46 70 509 77 61 Marie Elfstrand, Director Media Relations and PR, Tel. +46 8 45 45 734 SSAB is a Nordic and US-based steel company. SSAB offers value added products and services developed in close cooperation with its customers to create a stronger, lighter and more sustainable world. SSAB has employees in over 50 countries. SSAB has production facilities in Sweden, Finland and the US. SSAB is listed on the NASDAQ OMX Nordic Exchange in Stockholm and has a secondary listing on the NASDAQ OMX in Helsinki. www.ssab.com.

Aerocrine AB responds to recent speculation in the market

SOLNA, Sweden - Aerocrine AB (OMX Nordic Exchange: AERO) responds to recent speculation in the market. Aerocrine has noted recent speculation in the markets. The Board of Aerocrine confirms that it is in preliminary discussions with a third party concerning a public offer for Aerocrine. There can be no certainty that an offer will be made, nor as to the terms of any such offer. A further announcement will be made in due course. For more information about Aerocrine: Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336 Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or +46 709 695 219 Mats Carlson, Vice President of Global Operations, Aerocrine AB: +46 70 534 89 89 Or visit www.aerocrine.com About Aerocrine Aerocrine AB is a medical products company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO®.  Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007. Aerocrine is required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was submitted for publication at 08:00 p.m. on April 27, 2015.

Interim report January-March 2015

January-March 2015* ·Net sales for the first quarter amounted to SEK 3,251 million (2,695). ·Organic growth was 5 per cent (4). In addition, sales for the quarter were positively affected by currency gains and the acquisition of Rixonway. ·Operating profit amounted to SEK 211 million (156), corresponding to an operating margin of 6.5 per cent (5.8). ·Currency gains of approximately SEK 25 million (0) affected the Group’s operating profit, of which SEK 20 million (5) comprised translation effects and SEK 5 million (neg: 5) transaction effects. ·Profit after tax amounted to SEK 153 million (47), corresponding to earnings per share of SEK 0.91 (0.28). ·Operating cash flow amounted to SEK 34 million (132). * Comparative figures for 2014 were restated excluding Hygena, see page 6.Nobia Group summary       Jan Jan Apr -Mar -Dec -Mar 2014 2015 Change, 2014 2014/20 Change, % 15 %Net sales, SEK m 2,695 3,251 21 11,411 11,967 5Gross margin, % 40.1 40.0 – 41.0 40.9 –Operating margin 9.2 9.2 – 11.3 11.2 –before depreciationandimpairment, %Operating profit 156 211 35 975 1,030 6(EBIT), SEK mOperating margin, % 5.8 6.5 – 8.5 8.6 –Profit after 132 195 48 899 962 7financial items,    SEK mProfit/loss after 47 153 – -27 79 –tax including itemsaffectingcomparability, SEK mEarnings/loss per 0.28 0.91 – 3.20 3.82 19share excludingitemsaffectingcomparability, afterdilution,SEKEarnings/loss per 0.28 0.91 – -0.17 0.46 –share includingitemsaffectingcomparability, afterdilution,SEKOperating cash flow, 132 34 -74 779 681 -13SEK m All figures, except for net sales, profit after tax and operating cash flow, were adjusted for items affecting comparability.Additional information about items affecting comparability is provided on pages 6 and 9.Comments from the CEO“Nobia’s organic sales growth was 5 per cent for the first quarter. Net sales also increased as a result of favourable currency effects and the acquisition of Rixonway. Our two largest regions, Nordic and the UK, reported both healthy organic growth and improved profitability. Operating profit rose 35 per cent year-on-year. New websites are being launched for our brands this spring, and new, innovative kitchen solutions are being marketed in our stores. In 2015, we will open new stores and we are continuing to work on co-ordinating sourcing, optimising production and harmonising our commercial activities in our three regions,” says Morten Falkenberg, President and CEO.For further informationPlease contact any of the following on +46 (0)8 440 16 00 or +46 (0)705 95 51 00:- Morten Falkenberg, President and CEO- Mikael Norman, CFO- Lena Schattauer, Head of Communication and Investor Relations

Joachim Horn leaving Tele2 AB

Joachim Horn joined Tele2 and the Leadership Team in 2011 as Executive Vice President and CTIO and has held his current position since then. Joachim will take up a new position at a Telecom company in Asia. Niklas Sonkin, Executive Vice President Central Europe and Eurasia, will become acting CTIO for the Tele2 Group. Mats Granryd, President and CEO of Tele2 AB comments: “Joachim has been a great asset to the company and an appreciated colleague during these years. I would personally like to thank him for his hard work and contributions to Tele2. I wish Joachim the best of luck in his coming endeavors.” Joachim Horn comments: “I truly enjoyed my time at Tele2 and I’m glad I was able to contribute to the company’s success. I’d like to thank Mats for his great leadership and my colleagues and my fabulous team for an outstanding collaboration. I’m absolutely confident that Tele2 will continue to be successful in challenging the industry.” For more information, please contact:Lars Torstensson, EVP Group Communication & Strategy, Tele2 AB, Phone: +46 702 73 48 79 Viktor Wallström, Head of Public Relations, Tele2 AB, Phone: +46 703 63 53 27 TELE2 IS ONE OF EUROPE'S FASTEST GROWING TELECOM OPERATORS, ALWAYS PROVIDING CUSTOMERS WITH WHAT THEY NEED FOR LESS. We have 14 million customers in 9 countries. Tele2 offers mobile services, fixed broadband and telephony, data network services and content services. Ever since Jan Stenbeck founded the company in 1993, it has been a tough challenger to the former government monopolies and other established providers. Tele2 has been listed on the NASDAQ OMX Stockholm since 1996. In 2014, we had net sales of SEK 26 billion and reported an operating profit (EBITDA) of SEK 5.9 billion

BYD’s pure electric bus fleet on Schiermonnikoog judged No 1 in Netherlands

An independent survey of public transport passengers throughout the Netherlands in 2014 has rated the service of the fleet of six BYD pure electric buses on the holiday island of Schiermonnikoog as the best in the country. Compared to a national average satisfaction level of 7.4 the BYD ebuses operated by Arriva scored a very high figure of 8.4. The survey took into account the views of both bus and train passengers. The BYD buses were highly rated by passengers for their low noise levels, ease of boarding (entry level height) and overall comfort. The BYD ebuses in Schiermonnikoog have been in service for two years and during that time have achieved fuel costs savings of 26% compared with conventional diesel buses. These savings will mean that the electric buses – which are more expensive to buy – will have breakeven point of five to six years. Since it is planned to keep them in service for up to 15 years this will provide the operator with an attractive return. The buses and their drivers have been praised by Friesland Provincial Governor Johannes Kramer. His comments were sparked both by the economics of the ebus fleet but also by their ability to keep running in the adverse weather conditions often encountered on Schiermonnikoog. Local newspapers last December pictured some of the buses operating across a flooded roadway in heavy seas in order to return island visitors to their ferry back home. Isbrand Ho, Managing Director of BYD Europe (based in Rotterdam) said: “The Schiermonnikoog operators has proven beyond doubt the effectiveness, reliability and efficiency of our ebus. The buses there have performed really well despite some harsh climatic conditions”. About BYD BYD Company Ltd.  (http://www.byd.com/)is one of China’s largest companies to have successfully expanded globally. Specializing in battery technologies, their green mission to “solve the whole problem” has made them industry pioneers and leaders in several High-tech sectors including High-efficiency Automobiles, Electrified Public Transportation, Environmentally-Friendly Energy Storage, Affordable Solar Power and Information Technology and Original Design Manufacturing (ODM) services. As the world’s largest manufacturer of rechargeable batteries, their mission to create safer and more environmentally  friendly  battery  technologies  has  lead  to  the  development  of  the  BYD  Iron (http://www.byd.com/na/auto/FeBattery.html) Phosphate (or "Fe") Battery (http://www.byd.com/na/auto/FeBattery.html). This fire-safe, completely recyclable and incredibly long-cycle technology has become the core of their clean energy platform that has expanded into automobiles, buses, trucks, utility vehicles and energy storage facilities. BYD and all of their shareholders, including the great American Investor Warren Buffett, see these environmentally and economically forward products as the way of the future. BYD has made a strong entrance to the North, Central and South American markets with their battery electric buses, and lineup of automobiles. Their mission lies not just in sales growth, but also in sociological integration and local job creation as they have poured incredible investments into developing offices, dealerships and manufacturing facilities in the local communities they now call home, truly a first for Chinese companies. For more information, please visit www.byd.com  (http://www.byd.com/)or www.facebook.com/bydcompany (http://www.facebook.com/bydcompany). BYD EU PR Contact    penny.peng@byd.com+31 -102070888 Vareseweg 53,3047 AT, Rotterdam, Netherlands

Hale business celebrates record turnout and sales at launch of new exhibition

Clark Art in Hale played host to almost 500 guests on Thursday evening as it launched a new exhibition of work from Burnley artist Liam Spencer. The collection titled New Impressions, features over 60 classic scenes from Manchester, East Lancashire, and New York. One piece made up of 28 panels, the largest piece ever produced by the artist, sold for £15,000 on the night, with total sales over £130,000 – a record for the artist. Bill Clark, owner of the Ashley Road gallery, said: “Liam Spencer is one of the North’s most critically acclaimed and popular artists. During the last 15 years he has had exhibitions in all of the North’s important public galleries, including a retrospective at Manchester City Art Gallery in 2006. His work is now in major public and private collections all round the world. “It is an honour to launch his new collection at Clark Art, our customers are great fans of his vibrant impressionistic style.  It’s not often that you get a chance to meet and talk with such an important artist. “The exhibition is visually stunning and a rare opportunity to see so many of Liam's paintings in one place. “We are looking forward to welcoming more people through our gallery doors to view this unmissable collection.” The exhibition, New Impressions, runs at Clark Art  (http://www.clark-art.co.uk/)in Hale, until May 16th Web: www.clark-art.co.ukPhone: 0161 929 5150 Images:Clark 1 – L to R: Liam Spencer, Bill ClarkClark 2 – Visitors viewing ‘Times Square, Bubba Gump’, by Liam Spencer Ends

Members Honored at College of Optometrists in Vision Development 45th Annual Meeting

Six individuals received awards for their contributions to developmental optometry during the Awards Luncheon held at the 45thAnnual Meeting of the College of Optometrists in Vision Development (http://www.covd.org) (COVD), April 17, 2015, in Las Vegas, Nevada. Receiving recognition were Dr. Michael F. Gallaway, Dr. Carol Marusich, Certified Optometric Vision Therapist Jessica Stevenson, Dr. Lynn Hellerstein, Ms. Toni Bristol, and Ms. Michele Hillman. The 2015 A.M. Skeffington Award for outstanding contributions to the optometric literature in the areas of behavioral vision care and vision therapy was given to Michael F. Gallaway, OD, FCOVD. Dr. Gallaway is an optometrist on faculty at Pennsylvania College of Optometry at Salus University in Philadelphia and has been in private practice in the South Jersey area since 1989, specializing in vision therapy and children’s vision disorders. Carol Marusich, OD, FCOVD was awarded the 2015 G.N. Getman Award in recognition of her excellence in developmental optometry, her work as COVD International Examination and Certification Board Chair, and her contributions to the profession and her community. Dr. Marusich is in private practice in Eugene, Oregon and holds an adjunct faculty position for the Pacific University College of Optometry. The 2015 Certified Optometric Vision Therapist of the Year Award was given to Jessica Stevenson for her outstanding dedication to developmental optometry and patient care. Ms. Stevenson works for Dr. Carole Burns in Westerville, Ohio where she is the Clinical Director of Vision Therapy. The President’s Award was presented to two individuals, Lynn Hellerstein, OD, FCOVD, and Ms. Toni Bristol for their outstanding contributions to COVD -- Dr. Hellerstein for her continued dedication to expanding vision therapy through the Tour de Optometry program and for her leadership in board development, and Ms. Bristol for her continued dedication to furthering the success of vision therapy practices and increasing awareness of how optometric vision therapy changes lives.    Ms. Michele Hillman was presented with the Making Vision Therapy Visible Award for her efforts in educating the public about vision therapy. Ms. Hillman is the administrator of the Vision Therapy Parents Unite  (https://www.facebook.com/groups/VTparentsunite/)Facebook group. She was featured with her son in the April 9, 2014 press release A Missing Piece to the Autism Puzzle: College of Optometrists in Vision Development Shares the Visual Link to Autistic Behaviors (http://news.cision.com/college-of-optometrists-in-vision-development/r/a-missing-piece-to-the-autism-puzzle--college-of-optometrists-in-vision-development-shares-the-visua,c9567587). These awards are given annually at the COVD Annual Meeting Awards Luncheon. Nominations for the awards are reviewed by selection committees compiled of past award recipients, COVD members, and members of the Board of Directors. In addition, 30 travel grants and six travel scholarships were presented to optometry students and residents to help defer expenses for their attendance at the COVD meeting. COVD received donations from COVD members to help fund these grants and scholarships. Special thanks to Dr. Robert and Mrs. Linda Sanet for funding the four VT Resident travel scholarships; and to Drs. Richard Laudon, Celia Hinrichs, and Cathy Stern for funding the two NECO student travel scholarships.